YJP CEO Europe Forum
Abgar Barseyten (36) is co-founder and managing partner of the Tentamus Group. Before Mr. Barseyten decided to go independent with Tentamus, he was part of the M&A team and responsible for the development of the Food and Agri division of Intertek. In addition, Mr. Barseyten was responsible for Intertek’s Global Renewable Energy Business Unit out of Houston, Texas in the USA.
Mr. Barseyten began his career in 2004 in Corporate Finance with T-Mobile International in London, having studied Finance in Nürtingen, Germany and in Suwon, South Korea. In 2013, he obtained his Executive MBA from Kellogg.
Mr. Barseyten has been part of shaping the life science safety industry for numerous years across the globe by connecting dots across the labs, institutions and regulatory bodies.
Achim started EQS with a passion for Investor Relations and a clear vision which he has since transformed into one of the top providers for digital communications solutions in the Investor Relations business. In addition to founding and heading up the company, Achim Weick is also its largest investor.
Achim Weick graduated in business administration at the University of Augsburg. He laid the cornerstone of his career in Corporate and Investment Banking, which led to his working in Berlin, Budapest and finally New York.”
Adam is a senior business leader in the life sciences industry, with over twenty five years’ experience in a wide variety of international commercial and executive roles. A microbiologist by academic qualification and a sales and marketing specialist by professional training, Adam has worked for a number of leading technology-enabled service providers during his career, leading them through significant growth journeys and successful exits. He has an extensive network of contacts across the industry and a proven track-record with private financial and trade business owners. At Kinapse, Adam is responsible for the strategic growth of the business.
Mar. 1980 Bachelor Degree, Hokkaido Univ. Faculty of Engineering
Mar. 1982 Master Degree, Hokkaido Univ. Faculty of Engineering
Apr. 1982 Joined Mitsui Toatsu Chemicals, Inc..
Assigned to Ofuna Research Center
Apr. 1994 Manager, Electronic Materials Division
Feb.1996 Vice President, Image Polymers Europe(NL)
Jun. 1998 Executive Vice President,
Image Polymers Company (USA) and I.P. Europe(UK)
Apr. 2002 Director,Corporate Planning Division of Mitsui Chemicals
Apr. 2005 Director, Affiliates Management & Coordination Division
Apr. 2007 Director, Electronic & Information Materials Division
Aug.2008 President, Image Polymers Company
Apr. 2012 General Manager, Fine & Performance Chemicals
Division of Mitsui Chemicals
July. 2013 Executive Officer, General Manager, H-Project Division
April 2015 Executive Officer,
General Representative of Mitsui Chemicals in Europe
President and CEO, Mitsui Chemicals Europe GmbH
Chairman of Board, Heraeus Kulzer GmbH
April 2016 Executive Officer, Mitsui Chemicals Inc.
President and CEO, Kulzer GmbH
Family: Married, 3 sons
Favorite Pastime: Music, Travel
Alan I. Annex is Co-Chair of Greenberg Traurig’s Global Corporate Practice. He leads multi-disciplinary deal teams in a wide variety of large-cap and middle-market domestic and cross-border transactions. Alan has broad experience in corporate and securities matters, and regularly advises public company boards, special committees and executive management regarding their fiduciary duties; corporate governance best practices; and M&A deal strategies, structures and techniques. In addition, Alan has an active practice representing SPACs and UK Cash Shells in their IPO and business combinations.
is managing director and founder of the Evernine Group. Roth advises as communication consultant companies & publishers in their communication change management and performs in the industry as a keynote speaker on the subject of “modern self-promotion of companies in the digital age”. The economist also publishes in PC Welt online, Heise Online, T3N, Computerwoche & ChannelPartner.
Prof. Dr. Alexander von Erdély joined CBRE in July 2007 and set up the business lines Building Consultancy and Public Advisory Services in Germany. Since 2011, he has also been responsible for Global Corporate Services (GCS). From 2014 until June 2016 he was member of the executive board of both subsidiaries PREUSS and VALTEQ and responsible for their integrations process.
Prior to joining CBRE, Alexander was a Director at Ernst & Young from May 2001 to June 2007. Alexander has 20 years of experience in the management of teams for Strategic Advisory, CREM, Project Supervision and Management, Transactions, FM and Portfolio Services.
In April 2016, Alexander took over the role of Chief Executive Officer for CBRE Germany.
Education: Graduate Civil Engineer / Dr.-Ing. Civil Engineering Professor for Project Management of Refurbishment Projects, Hochschule für Technik und Wirtschaft Berlin
After having grown up in Turkey and finishing his MSc in Engineering at ETH Zurich, Alparslan joined a Swiss multinational company to build up their engineering composites division, for which he was appointed as a General Manager very early in his career. This lead to a successful build-up, EXIT (was no more core business) and integration in another multinational group. Alparslan then joined a micro precision components company as the CEO of the group, transformed this ailing company to a well-positioned and respected group. This 10 years operation involved turn around, growth, management buyout, crisis management (2001/2002), BOD assignment and EXIT. After this period, Alparslan had various CEO and Chairman (another management buyout) assignments in the field of renewable energy solutions for buildings, energy transfer components and industrial digital printing equipment businesses. As of mid-2013, he joined SFC KOENIG GROUP, another PE-backed group to implement the next growth trajectory. Alparslan completed his management training at Stanford, Harvard and INSEAD. He is a sailor, passionate philosophy reader, a film buff and piano player. He
speaks Turkish, German, English and French.
After completing his industrial engineering degree in 2002, Amir Roughani moved from Berlin to Munich to gain his first industrial experience with the KirchGruppe. With the demise of the media group he received a redundancy payment which enabled the first step toward becoming a self-employed entrepreneur. At the age of 27, he founded the current VISPIRON in Freising near Munich. From home, he began to acquire his first projects in the technology services sector and develop business partners.
Since then, his business enterprise has grown to employ 500 people in the technology sector. He supplies mechatronics based products and services in the automotive, telecommunications, industrial and renewable energy sectors through four divisions: Engineering (development partner for electrical / electronic components), Metrology (world leader for torsional vibration analysis), Fleet Management (electronic logbook, license control, battery management, car sharing) and Energy (system integrator for solar, wind and pumped storage power plants). The latter provides green electricity for around 50,000 people. The annual group turnover of around 50 million euros is increasingly generated in the areas of "digitalisation" and "renewable energy".
In 2014 he received the "Entrepreneur of the Year" award from Ernst & Young in the field of IT and Services. The magazine "Capital" lists Roughani among the top 40 young entrepreneurs in the business sector in Germany. His group has repeatedly been nominated to the list of "Best Employers in Germany". As a serial entrepreneur, he is committed to climate protection and supports a variety of social projects.
Since January 2014 André Maeder is the CEO of The KaDeWe Group. He has a long-standing international career in retail as well as fashion brands, especially in the premium and luxury segment. Thus he was, among other things, for six years as Chief Retail and Merchandise Officer at Harrods in London. From 2004 to 2009 he was Global Retail and Sales Manager at Hugo Boss in Metzingen and subsequently CEO at the Charles Vögele Group in Switzerland.
Before his current position he worked as Chief Retail Officer from November 2011 to December 2013, in this position he was responsible for all distribution lines at Karstadt Warenhaus GmbH in Essen.
Years in IT Business: 18
Other Related Experience:
Serial Entrepreneur, Speaker, Mentor &
Investor, Digital Strategist
Member of different global Advisory Councils
Located in Munich
Nutrition and Fitness Fan
Assaf Halevy is the founder and chief executive officer of 2bPrecise, LLC, leading a team dedicated to inventing new products, services and solutions that target genomics and precision medicine at the point of care and research.
In 2013, he joined Allscripts as senior vice president of products and business development when the company acquired dbMotion. As an initial inventor and co-founder of dbMotion, Halevy helped develop one of the foremost clinical integration and population health management platforms in the industry today.
While at dbMotion, Halevy served in key leadership roles that influenced the company’s rapid growth and success. Those roles included international operations, strategic accounts, products, and innovation. After founding dbMotion, Halevy moved to the US and helped build the US operations of the company. He was instrumental in introducing dbMotion’s semantic interoperability to the US market in 2005, where it quickly became one of the leading health information exchange solutions, adopted by dozens of leading provider organizations across the country. dbMotion was ranked number one interoperability solution in KLAS for several years and won many industry awards.
Halevy has thirteen pending patents in the areas of actionable clinical integration and interoperability as well as in precision medicine. He extends his industry expertise by evaluating strategic alliances and partnerships for US and international markets. His vast practical knowledge and experience in building Health Information Exchange networks in many countries, some of which are at the state level, contributes to his significant influence and support for the healthcare industry. Halevy was invited to participate in several US government activities and contribute in a HHS privacy committee task force. In 2016, he was part of a small selective group of executives invited to the White House by Vice President Joe Biden to discuss the future of interoperability.
Halevy holds a Bachelor of Science degree in computer science, with honors, from the Academic College of Tel Aviv-Jaffa and Tel Aviv University, as well as a Genomics and Genetics certification from Stanford University.
Axel is CEO of WSCAD, a company delivering CAD software for electrical engineering. In three years Axel turned the company around, grew revenues 57% and achieved the Nr. 2 status in Central Europe. In his previous role Axel led a business unit at EPLAN, a German electrical CAD software company where he doubled profits and revenues within 3 years. His unit has been awarded for two consecutive years as the fastest growing business unit in the company. Axel is an IBM alumni. During his 15-years tenure at IBM he had several positions in marketing, sales and management and received various awards. Axel graduated in Computer Science (M.Sc.) and has a Ph.D. in business administration, both from the University of Stuttgart, Germany. He holds several certificates from the Jack Welch Management Institute, USA where he also held several management trainings.
Bastian Nominacher is a thought leader in the field of Process Mining and Big Data Analytics. He is the co-CEO and co-Founder of Celonis, the leading global supplier of Process Mining. As such, he is responsible for the global GTM operations and the company’s strong partnership with SAP. Before founding Celonis in 2011, Bastian worked for Ernst & Young, Accenture, IBM and United-Domains. He graduated in Information Systems Management & Financial Mathematics from TU Munich. He is also the author of several academic papers in the area of IT Carve-outs and Post-Merger-Integration.
Bernard Munos, M.B.A., M.S., is a Senior Fellow at FasterCures, a center of the Milken Institute, and the founder of the InnoThink Center for Research in Biomedical Innovation, a consultancy that helps biomedical research organizations become better innovators. Before that, he served as an advisor for corporate strategy at Eli Lilly, where he focused on disruptive innovation and the radical redesign of R&D. He is also a member of the Forum on Drug Discovery, Development, and Translation at the National Academy of Medicine; a member of the Advisory Board of Science Translational Medicine; a non-executive Director of Glenmark Pharmaceuticals; a Board member or Advisor to a dozen other companies or publicly-financed research organizations; and a former member of the Advisory Council of the National Institutes of Health’s National Center for Translational Sciences (NCATS). His research has been profiled by Forbes magazine; and the popular industry newsletter FiercePharma named him one of the 25 most influential people in biopharma. He received his MBA from Stanford University, and holds other graduate degrees in animal science and agricultural economics from the Paris Institute of Technology for Life, Food and Environmental Sciences and the University of California, Davis. He blogs about biomedical innovation on the Forbes website.
Dr. Bernick is Co-Founder, Director and Chief Clinical Officer of TherapeuticsMD (TXMD), an innovative women's health company exclusively focused on developing and commercializing products for women throughout their life cycles. Currently, TXMD is focused on the development and commercialization of advanced hormone therapy pharmaceutical products with two drugs having completed phase 3 clinical studies and pending FDA approval. In addition, TXMD through its subsidiary vitaMedMD manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter, or OTC, vitamins.
Dr. Bernick has 25 years in the women's health arena and is an award-winning Ob/Gyn recognized by colleagues as top 1% of obstetrics & gynecology practitioners. He is a world's expert in Menopause with multiple publications and presentations as well as multiple patents related to hormone therapy and pharmaceuticals.
Brian A. Leuthner has been the Co-Founder, President and CEO of Edge Therapeutics, Inc. since its inception in January 2009 and has also served on our board of directors since such time. He has more than 27 years of experience in the hospital acute care marketplace, with a specific expertise in critical care and neurocritical care. Prior to founding our company, Mr. Leuthner was the CEO of Fontus Pharmaceuticals, Inc., the Senior Head of Marketing for The Medicines Company (NASDAQ: MDCO) and the Director of Market Development for ESP Pharma, Inc. He also held marketing and sales positions of significant responsibility at Burroughs Wellcome and Company, Glaxo Wellcome plc and Johnson & Johnson (NYSE: JNJ). In these leadership roles, he helped create and advance hospital business units, develop and launch new critical care products and strengthen customer relationships. Mr. Leuthner received the EY Entrepreneur Of The Year™ 2015 New Jersey Region Award in the “Pharmaceutical & Diagnostic Private Companies” category. Mr. Leuthner serves a Board Member for the Brain Aneurysm Foundation. Mr. Leuthner received his B.S. and M.B.A. degrees from the University of North Carolina at Chapel Hill.
Burkhard Kieker has been Chief Executive Officer of visitBerlin (Berlin Tourismus & Kongress GmbH) since 1 January 2009 and is thus the city’s senior tourism & meetings advertiser. He previously headed the Marketing and Corporate Communications department of Berlin Airports for many years. Alongside classic communication, his tasks at Berlin Airports included acquiring and supporting airlines from more than 60 countries in particular. Kieker is a trained journalist (DIE ZEIT, Deutsche Welle TV).
Prof. Dr. Cai-Nicolas Ziegler is CEO of XING Events (formerly amiando), which is part of XING, Germany’s major business-related social network. At the same time, he is Professor for Artificial Intelligence at Albert-Ludwigs-Universität in Freiburg.
Before joining XING he was in charge of PAYBACK’s digital product management departments, Europe’s leading coalition loyalty program. Cai has been with BCG, the Boston Consulting Group, as strategy consultant from 2008-2011 (career step Project Leader).
He obtained his Ph.D. and venia legendi (“Habilitation”) in Artificial Intelligence, doing research on recommender systems and machine learning.
Carsten Brockmeyer is a pioneer and expert in Biopharmaceuticals and Biosimilars. Carsten is the CEO of Formycon AG, for which he has helped to raise significant funding. According to the German FOCUS Magazine, Formycon is the fastest growing Pharma/ Biotech enterprise in Germany. Formycon is focusing on the development of Biosimilars, a new class of medicines, which are taking over the role of Generics in the future Healthcare Systems. Formycon’s main indications are in Ophthalmology and Autoimmunity. Before joining Formycon, Carsten has held leading management positions at Baxter, Hexal, and Sandoz/Novartis. From 1998 to 2009, he was General Manager of Hexal Biotech GmbH, where he oversaw the development of the world’s first biosimilar epoetin alfa (Binocrit®), a game changer in anemia therapy, launched in 2007 by Sandoz/Novartis. Carsten founded Brockmeyer Biopharma GmbH in 2010, a pharma and biotech consultancy, and helped to established Formycon AG in 2012. Carsten holds a doctoral degree in human biology. His work in the field of biopharmaceuticals has been recognized with prestigious scientific awards. The British journal “The Medicine Maker” has ranked Carsten repeatedly among the 100 most influential leaders in pharma.
Dr. Christopher Anzalone is President and Chief Executive Officer of Arrowhead Pharmaceuticals, Inc., a Nasdaq listed (ARWR) biopharma company developing therapeutics based on the cellular mechanism of RNA interference. Prior to Arrowhead, Dr. Anzalone formed and served as CEO of the Benet Group LLC, a private equity firm focused on creating and building new nano-biotechnology companies from university-generated science. Prior to his tenure at the Benet Group, he was a partner at the Washington, DC-based private equity firm Galway Partners, LLC, where he was responsible for sourcing, structuring, and building new business ventures. Prior to Galway, Dr. Anzalone was an NIH-supported post doctoral fellow in Reproductive Endocrinology at the Smithsonian Institution’s Conservation and Research Center. Dr. Anzalone holds a Ph.D. in Biology from UCLA and a B.A. in Government from Lawrence University.
Christian started out in the Internet at the very early stages of the industry. He held various leadership roles at global players like Microsoft, Bertelsmann, AOL, and CompuServe, when they were at the forefront of the competition. He managed corporate headquarters positions as well as several field operations – but ultimately wanted create his own business. He founded Experteer with the Mission to be the No 1 source for high-end positions trusted by candidates & recruiters.
Today Experteer is Europe’s premium career & recruitment network with more than 6 million professionals and executives, who use Experteer as their trusted source to the high end job market. Senior-level candidates can access thousands of positions with salaries benchmarked at 60,000 € or higher, and confidentially network with thousands of recruiters across Europe. Experteer has a highly international team, with employees from more than 30 countries. The company is headquartered in Munich, Germany
Christian studied in Munich, Berkeley, and St.Gal. He holds a masters in business with distinction and completed a Ph.D. on ‘Business Strategy in the Online Industry’ during the heydays of the Internet.
Christian Tidona is a serial biotech entrepreneur, business angel, and managing director at the BioMed X Innovation Center in Heidelberg, Germany. He studied molecular biology and received his doctoral degree from the University of Heidelberg. Throughout his entire professional life his focus has always been to foster innovation at the interface between academia and industry. Christian is board member of the BioRN Network and co-founder of the Health Axis Europe alliance between the European health innovation clusters in Leuven, Maastricht, Copenhagen, and Heidelberg. He is chairman of the Weizmann Young European Network (WYEN) and member of the International Board of the Weizmann Institute of Science in Israel. Christian is married and father of two children.
Christian Uloth (23) is the CEO of AIESEC in Germany since August 2017. AIESEC is the world’s largest youth driven organization and has 60 years of experience in developing high-potential youth into globally minded responsible leaders. It offers young people the opportunity to participate in international internships, experience leadership and develop in a global learning environment.
Before taking over the CEO role Christian studied Finance at the Goethe University of Frankfurt and led the local chapter of AIESEC in Frankfurt were he managed to grow in revenues and the relevant KPI of delivered internships by more than 100% in one year, delivering one of the three best performances in AIESEC in Germanys history that started in 1952.
Christoph Meinel (Univ. Prof., Dr. rer. nat., Dr. sc. nat., 1954) is CEO and Scientific Director of the Hasso Plattner Institute for IT Systems Engineering GmbH (HPI) at the University of Potsdam. He is full professor
(C4) for computer science at HPI and the University of Potsdam, and he holds the chair of Internet Technologies and Systems. Meinel is a member of the National Academy of Science and Engineering (acatech), Chairman of the German IPv6 Council, and director of different project
groups in the German National IT Summit. He is a member of
numerous scientific committees and supervisory boards,
such as the SAP Security Advisory Board, and, together with
Larry Leifer, leads the program of the HPI Stanford Design Thinking Research Program.
Meinel’s research in Internet Technologies and Information Systems focuses on
- “Security Engineering” (Network, IPv6, SOA and Internet Security,
Identity and Trust Management, and Security Usability) and
- “Knowledge Engineering” (Educational technologies and MOOCs,
Social Media Analytics, and Web 3.0 – Semantic, Social, Service Web)
In addition, he is scientifically active in the field of
- Innovation Research and Design Thinking.
Earlier work concentrated on the field of complexity theory, and efficient algorithms and data structures, particularly in the area of binary decision diagrams (BDDs). Meinel teaches courses on IT Systems Engineering in the HPI Bachelor and Master Degree programs, serves as doctoral supervisor, and teaches at the HPI School of Design Thinking. He was conferred the title of honorary professor at the TU Beijing, visiting professor at Shanghai University, concurrent professor at the University of Nanjing. Meinel served as a senior researcher fellow at the Interdisciplinary Centre for Security, Reliability and Trust (SnT) at the University of Luxembourg.
Meinel is author or co-author of more than 25 books, anthologies, as well as numerous conference proceedings. He has had more than 550 (peer-reviewed) papers published in high-profile scientific journals and at international conferences and holds a number of international patents. He additionally directs the development and operation of the MOOC platform “openHPI” as well as he provides a space for expert group discussions on the “Education Cloud” and the “School Cloud”. Meinel studied mathematics and computer science at Humboldt University in Berlin from 1974–1979 and in 1981 received his PhD, graduating Dr. rer. nat. In 1988 he completed his habilitation as Dr. sc. nat. at the Institute for Mathematics at the Academy of Science in Berlin. Following a research stay at the University of Saarbrücken and a visiting professorship at the University of Paderborn, he was appointed full professor (C4) of computer science at the University of Trier in 1992. Between 1998 and 2002 Meinel served as director and managing director of the Institute for Telematics in Trier eV. Between 1996 and 2007 Christoph Meinel was a member of the scientific board of directors of the IBFI Schloss Dagstuhl and speaker of the German Informatics Society (GI) specialist group, “Complexity”. He has received numerous teaching invitations from within Germany and abroad, organized a wide range of international symposia and conferences, and led or participated in many scientific program committees.
Daniel Nathrath is founder and CEO of Ada, an AI health companion that helps people assess their health and provides doctors with diagnosis decision support. Grounded in six years of R&D, Ada launched in late 2016 with the mission to give everyone access to high quality, personalised health information and care. Ada has over one million users, growing 60% MoM, and has been piloting its decision support technology with NHS practices, research institutions and providers in Germany. Nathrath helped transform Ada’s sophisticated AI technology into a global, digital health solution and has been involved with several startups in Germany, Denmark, the UK and U.S., as Founder, Managing Director and General Counsel. Prior, he was a consultant at BCG and trained as a lawyer in the U.S. and Germany, where he was a Fulbright Scholar. Nathrath holds an MBA from the University of Chicago.
Dieter Weinand has been a member of the Board of Management of Bayer AG and President of the Pharmaceuticals Division, headquartered in Berlin, Germany, since January 1, 2016. He joined Bayer on August 1, 2014 as head of the Pharmaceuticals Division.
During a career stretching back over 25 years, he has held various positions in commercial, operational and strategic areas of the pharmaceutical industry. These included responsibilities spanning various therapeutic areas and geographies for companies, such as Pfizer and Bristol-Myers Squibb.
Weinand earned an M.S. in pharmacology and toxicology from Long Island University, New York, and a B.A. in biology from Concordia College, New York.
Drenusha Shala was born in November 1989 in Prizren. At the age of 7, she moved to Switzerland with her family.
She has completed her professional high school for business and administration in Zurich. During this period she worked for 3 years as a Junior Project Manager at Zurich Financial Services, which was her first and last employer.
Drenusha, together with Flamur Shala and Muhamet Veliu, set up a new business, Baruti GmbH. At that time she was only 21 years old. Consequently, following Barut's growth, she has completed her Bachelor degree at the University of St. Gallen for Management
In 2013 she was elected Chief Executive Officer of Baruti AG.
Dr. Esteban Pombo-Villar, is Chief Executive Officer of TargImmune Therapeutics, a biopharmaceutical company focused on the development of novel immuno-oncology therapeutics, based in Basel, Switzerland. Previously he was Chief Operations Officer (COO) for Oxford BioTherapeutics, and a Member of their Boards of Directors. Prior to joining Oxford BioTherapeutics, Dr. Pombo-Villar was at Novartis and Sandoz for over 23 years, the last 12 years engaged in Business Development and Alliance Management, and as Head of Alliance Management at the Novartis Institute for Biomedical Research (NIBR). Prior to that he served in several roles as medicinal chemist in the Neuroscience research group. He obtained a PhD, MSc and BSc in organic chemistry from the University of Warwick (UK), was a visiting researcher at the University of Newcastle upon Tyne (UK), and completed postdoctoral studies at the ETH in Zurich. Dr. Pombo-Villar is a Fellow of the Royal Society of Chemistry, member of several scientific societies and has completed executive business studies at IMD (MTE, Lausanne), Harvard Business School (US), and the Tuck School of Business (Dartmouth, US). A native of Bogotá, Colombia, he lives in Switzerland since 1986.
Tech CEO and Founder based in Berlin. Passionate about building organizations, helping people grow, and crunching data. Former McKinsey consultant. WHU/LBS/HEC educated.
CEO & Co-Founder
October 2012 – Present
McKinsey & Company
September 2008 – September 2012 (4 years 1 month)
Helped clients deliver organizational change while working in small project teams reporting directly to the top management.
- European insurance group: implemented a $3bn merger of two subsidiaries
- Global investment bank: cut $1bn per year in fixed cost
- European asset manager: reduced $300m per year in backend complexity
- Global Private Equity group: conducted a due diligence on a $30bn buy-out target
- German wholesale bank: evaluated an $18bn automotive credit portfolio
- Global automotive supplier: prepared for a $15bn IPO
Frank Niehage has vast experience across all segments of retail and commercial banking, having previously been Managing Director at Goldman Sachs until August 2014. In previous positions, he was instrumental in the growth of Bank Sarasin AG as CEO in Germany. Prior to this he had served in various senior positions at Commerzbank, Credit Suisse, UBS and international law firm Beiten Burkhardt, both in Germany and internationally, especially Asia. Frank is an attorney at law in Germany and has received his Master of Laws majoring in international economics from the University of Houston Law Center.
Frédéric Monard (38) has been CEO of the PIDAS Group since April 2014. Under his leadership, the company has grown fast to more than 350 employees and was able to significantly extend its customer base in Switzerland, Germany and Austria. PIDAS is now well positioned as the leading Customer Care Company, providing management consulting, developing intelligent software products (using AI-technologies such as Natural Language Processing and machine learning) as well as delivering top-notch and highly automated remote IT-services around the world. With his management team, he invested most of his time in company culture and values, business development and innovation. Before this, Frédéric Monard newly and very successfully established the PIDAS Consulting business. As a management consultant, he realized numerous projects for renowned companies in Switzerland, Germany, Austria, France and Spain. His academic background includes a degree in Business Economy, an Executive MBA as well as a leadership program at the renowned Harvard Business School in Boston (USA). The passionate leader specializes in strategic customer care management in business and IT, digitalization in customer service as well as in the transformation of organizations towards lived customer orientation. His fluency in several languages and a distinctive cultural empathy (stays abroad in South America, China and USA) complete his profile.
Originally from the French-speaking part of Switzerland, Frédéric Monard works in Zurich and lives in Basel. He is married and proud father of two children.
Frederic Nze is the founder and CEO of Oakam, a digital micro-lender that is expanding credit access for the UK’s 12 million financially-excluded consumers. Oakam has captured the opportunity presented by the rapid democratization of smartphone technology to disrupt micro-lending by making borrowing more affordable and accessible for the working class. Prior to founding Oakam, Frederic spent his career in credit risk management and consumer finance at firms including American Express, Barclays and GE Capital. He first came across the UK’s micro-lending opportunity while working on a pilot project at Barclays to evaluate product offerings for lower income customers, and realizing the potential of this market, decided to found Oakam in 2006. Raised in Cental Africa, Frederic saw firsthand how informal community lending helped to jumpstart entrepreneurs and fledgling businesses. With global ambitions for Oakam, Frederic’s ultimate goal is to bring the concept back to the developing world.
Dr. Geert Cauwenbergh was appointed president and CEO of RXi Pharmaceuticals Corporpation in April 2012. Prior to joining RXi,
Dr. Cauwenbergh served as chairman and CEO of Barrier Therapeutics Inc., a publicly traded biopharmaceutical company he founded in 2001 that focused on dermatology drug development. Barrier was acquired by Stiefel Laboratories Inc. in 2008. Prior to founding Barrier, Dr. Cauwenbergh held a number of ascending senior management positions at Johnson & Johnson, where he was employed for 23 years. As Vice President, Research and Development for Johnson & Johnson's Skin Research Center, he was responsible for the worldwide research and development of all skin care products for Johnson and Johnson's consumer companies. He is a member of the board of directors of Phosphagenics and Moberg Pharmaceuticals. In 2005, Dr. Cauwenbergh was inducted into the New Jersey High-Tech Hall of Fame, and, from 2009 to 2010, he served as chairman of the board of trustees of BioNJ. He has authored more than 100 publications and has been a guest editor for a number of books in mycology and infectious diseases. Dr. Cauwenbergh received his doctorate in medical sciences from the Catholic University of Leuven, Faculty of Medicine (Belgium), where he also completed his masters and undergraduate work.
Gero Decker is co-founder and CEO of Signavio, a Berlin-headquartered software company specialized in Business Process Management. Signavio has offices in 7 countries, was awarded as one of Germany's fastest growing companies and ranked as second best company to work for in Berlin. Gero holds a PhD in Software Engineering from Hasso-Plattner-Institute in Potsdam and was named the "Innovator of the Year" by MIT Technology Review in 2016.
In early 2016 Mr. Buscetto became CEO of Healthcare Highways Rx bringing more than 34 years of experience in pharmacy benefit management, managed healthcare, healthcare IT, and mergers & acquisitions. Mr. Buscetto has spent the last 16+ years focusing his career in pharmacy benefit management (PBM), beginning in 2001 with ProCare Rx, a privately held PBM in Duluth Georgia, where he held various senior level positions during his 6 year tenure, he guided the company from a claims processor to a PBM with 12 million lives departing as Chief Operating Officer in 2007.
In 2007 Mr. Buscetto joined SXC HealthSolutions as Senior Vice President & General Manager where during his tenure he transformed the company from a claims processor to the 4th largest PBM in the country departing as Segment President, Strategic Solutions in early 2014.
In 2014 Mr. Buscetto founded Leading Business Consultants in Braselton, Georgia, serving clients in the healthcare industry with strategic projects mergers and acquisitions and other transactions, as well as payroll enhancement programs. Mr. Buscetto began his career as an internal auditor for the Farm Credit System and worked for various boutique investment banking & brokerage firms. Mr. Buscetto is a graduate of the Indiana State University and holds a Bachelor's degree in Accounting with a minor in Computer Science.
Gregory Ellis was appointed Chief Executive Officer (CEO) of Scout24 Group in March 2014. He is responsible for all commercial operations of the company.
Ellis has more than 20 years of international business experience within the digital media industry. He joined from REA Group (a multi-country digital classifieds platform specialized in property based in Australia) where he was Managing Director and CEO for more than five years. In his years at REA, Ellis and his team achieved outstanding growth rates and a share price increase of more than 350% over the course of 5 years (30 Dec 2009 – 30 Dec 2014).
Prior to joining REA Group in September 2008, he was Marketing Director for Online Services at Microsoft Asia. Previous roles included Managing Director of Online for Truvo BV, as well as Managing Director of Sensis Interactive and Group Marketing Manager for Telstra Corporation.
Hans Szymanski is CEO of NFON AG. Prior to joining NFON in July
2016, Mr Szymanski served as CEO and CFO at stock listed Francotyp
Postalia Holding AG for seven years. With more than 20 years’
experience in C-level positions at companies such as Jenoptik Laser,
Optik, Systeme GmbH and Dematic GmbH, he has achieved significant
success in the restructuring as well as strategic development of small
and medium-sized companies as well as corporations.
Mr Szymanski is a full-blooded entrepreneur with extensive experience
spanning various industries in national and international trade,
production and technology fields. Mr Szymanski is a graduate of the
Ruhr-Universität Bochum and holds a degree in economics.
Hartmut Hahn founded Userlane with the intention to make the web more accessible for everyone and help companies explain software to their users and employees the easiest way possible.
Hartmut is an entrepreneur, digital strategist and consultant and regularly speaks at conferences on the future of digital business models. He holds a master’s degree in economics, looks back on a career in strategy consulting and worked at the international media corporation Hubert Burda Media, where he developed digital growth strategies and lead M&A projects.
Born 1978 in Lebanon and grown up in Beirut, Hassan Kadbi joined Hapimag in 2005. First as a Resort Manager in Bodrum, then later as an Area Manager for Greece, Morocco and Turkey and finally as a Chief Resorts Officer and a Member of the Executive Board. He was responsible for all the Hapimag resorts before he became CEO in November 2016.
Hassan Kadbi holds a Bachelor of Arts in International Hospitality and Tourism Management at the University of Bournemouth (GB) and a Higher Diploma in Hotel Management at the IHTTI School of Hotel Management in Neuchâtel (CH). Before he joined Hapimag he worked in various management positions in different international companies in Lebanon, Greece, Cyprus and Great Britain, the last one was Hilton. He also realized some projects in Asia.
Prior to establishing the Fund, Helen was a partner of Deloitte and led Deloitte’s Life Sciences industry practice in Australia for 5 years, having had many years’ experience in the Life Sciences and Health Care industry, achieving almost 30% growth year on year throughout her tenure. She also specialised in Funds Management, servicing some of the largest funds in the Funds Management industry and has assisted in setting up a number of large international funds, as well as advised on a number of significant M&A deals . Helen provided strategic tax advice to publicly listed and large multinational companies and is experienced with capital raisings, licensing deals, demergers, implementing offshore structures, intellectual property management and location, and supply chain management.
Biotechnology executive with over 30 years of experience in preclinical development of therapeutics in multiple areas, including cancer, diabetes, inflammatory and autoimmune diseases and stem cells.
Participated in preclinical research team for the novel Type 2 diabetes drug that successfully completed Phase 2 trial, resulting in $350MM licensing deal with Sanofi-Aventis. Highly involved in technical, strategic and business development planning for Wellstat companies (see www.wellstat.com).
Irena Tsyrlova received her medical degree from the State Medical Institute, Novosibirsk, Russia, and obtained her PhD and DSc in Immunology-Hematology from the Institute of Immunology, Moscow, she had established and led the laboratory of Molecular Biology of Hematopoiesis. One of the pioneers of the stem cell research in Russia, she authored “The Hematopoietic Stem Cell and the Immune Response” (with V. A. Kozlov and I. N. Zhuravkin, “Nauka” Publishing House), several patents and one discovery registered by the State Committee of USSR. Additionally, she has trained 10 PhD students. As a Research Fellow she spent a year at the Christie Hospital and Paterson Institute for Cancer, Manchester, UK, and participated in the preparation for the world's first use of cultured bone marrow for leukemia treatment and the world's first single harvest blood stem-cell transplant under Prof. Michael Dexter; and later spent 6 months at the Terry Fox Lab, Vancouver, Canada, working on the development, validation and use of quantitative assays specific for hematopoietic stem cells, in collaboration with Dr. Connie Eaves.
Dr.Tsyrlova has 20 years of management experience as an operational manager and a strategic leader within an international biotech environment, advancing development efforts directed toward the use of hematopoietic stem cells in regenerative medicine, as well as for hemo- and radioprotection of stem cells during cancer-related therapy. She served as a Director, Stem Cell Biology (2001-2013) at Wellstat Therapeutic Corporation, a private biotech company located in Gaithersburg MD, USA, where she designed and led preclinical and participated in clinical studies on stem cells and new drug candidates development as well as contributed to the research and clinical programs in diabetes, inflammatory and autoimmune diseases (including a diabetes drug licensed to Sanofi for $350MM). Prior to that she was a Director, Hematology, Pro-Neuron, Inc. Rockville, MD, USA, where, in addition to leading a lab, she established important partnerships with industry and other research institutions on cord blood expansion (with Dr. Visser, New York Blood Center); protection of stem cells from chemotherapy (with Dr. Moore, Memorial Sloan-Kettering Cancer Center NY); gene transfer of MDR gene into stem cells with (with Dr. Bank, Columbia University); improvement of stem cells engraftment after transplantation (with Dr. Ploemacher, Rotterdam University, Holland); and others.
In addition to being an expert in immunology, hematopoietic stem cell biology with a solid background in gene and cellular therapy principles, blood banking and stem cell expansion, Dr. Tsyrlova has maintained a keen interest and hands-on mastery in developing and adapting novel, cutting edge research applications, including animal models, flow cytometry-based assays, gene therapy applications, cell assays and small scale manufacturing processes.
Importantly, she played an active role in the design and implementation of the clinical research program for the hematopoietic stem cell inhibitor-cell cycle regulator (including IND submission, clinical protocol development, Key Opinion Leader and Health Authorities interactions, and certain aspects of clinical study management) and participated in preparation of several other IND, as well as one Investigational Device Exemption Application. She has lead discussions with the Office of Cellular, Tissue and Gene Therapies, CBIR, US FDA, and in the FDA advisory committee meeting on the topic of cellular replacement therapies.
Dr.Tsyrlova`s exposure to the regular venture and Business Development and Licensing (BD&L ) presentations and negotiations has led to a keen understanding of the financial elements of pharmaceutical development. She has participated in writing Small Business Innovation Research (SBIR) Grants leading to multi-million dollar funding for programs in gout, Type I diabetes, cancer, multiple sclerosis (MS) and inflammatory diseases.
From 2013 till present she has been working as Independent Biotechnology Consultant advising startup and established biotechnology companies in Eastern Europe on the clinical development strategies, intellectual property and regulatory issues in the USA. She has been often invited to deliver talks and seminars like
• “Cord Blood Cells in Regenerative Medicine” (October 2013)
• "Bench to Bedside – Translation of Therapies to the Clinic” (June 2014)
• "3d Bioprinting from the FDA perspective" (October 2014)
Mr. Riley, a member of the Synthetic Biologics Board of Directors since March 2010 and Chairman of the Board from November 2011 to May 2012, was appointed as the Company’s President and Chief Executive Officer in February 2012. He has more than 20 years of experience in the biotechnology and pharmaceutical industries during which he negotiated numerous worldwide strategic corporate alliances, established joint ventures, and assisted in obtaining venture financings to support product development. Most recently, in addition to serving as Synthetic Biologics’ Chairman, where Mr. Riley played an integral role in the formation of the Company’s collaboration with Intrexon Corporation, he served as Managing Director of 526 Ventures, a life science-focused venture consulting firm with a commercial and traditional focus. Prior to this, he was a venture partner with QIC Bioventures Fund, the life science-focused venture component of the $70 billion Australian-based Queensland Investment Corporation (QIC). Over his career, Mr. Riley held senior positions within the mergers & acquisitions and in country management groups at both SmithKline Beecham and Pfizer. Additionally, he served as CFO and VP Corporate Development for Nichols Institute Diagnostics, later acquired by Corning and spun out to Quest Diagnostics, Inc. (NYSE: DGX). Mr. Riley holds a Bachelor of Science degree from Boise State University, completed coursework at UCSF/Berkeley in drug discovery/development and participated in a dual-degree graduate program (MBA/MIM) sponsored by Arizona State University and the Thunderbird School of Global Management.
Following the merger of Spark Networks Inc and Affinitas GmbH, Jeronimo Folgueira will take the role of CEO of the combined entity, Spark Networks SE, which operates JDate, the world’s leading Jewish dating service. Other iconic brands in the company’s portfolio are EliteSingles, eDarling, Attractive World, ChristianMingle and JSwipe. The merged company will be based in Berlin, Germany, and remain listed in the New York Stock Exchange (NYSE:LOV).
Before joining the company in October 2015, Jeronimo was the International Managing Director of Betfair, based in Dublin. Jeronimo has also held senior executive roles at Bigpoint and RTL Group among others. Jeronimo started his career in London as an M&A investment banker at Lehman Brothers and later on at Citigroup.
With an Economics degree from the University of Navarra and an MBA from Columbia Business School, Jeronimo has nearly 15 years of experience within the technology and media space.
Jonathan Bloch studied Law at the University of Cape Town and the London School of Economics. He went into business and was a main board director of a listed publishing company. Subsequently he established his own business Information Publishing Plc (IPP) for which he serves as CEO. It operates on four continents and employs 400 people.
He is also Chairman of Company Watch, a company ratings agency. He has been actively involved in politics starting in South Africa at the age of 18 and was a councillor in London for 12 years. He sits on numerous charitable and campaign boards.
Dr. Jürgen Friedrich has been CEO of Germany Trade and Invest
since May 2009.
From August 2007 to May 2009 he directed the North Africa and
Middle East department at the Federal Ministry of Economics and
Technology in Berlin.
In the years from 2000 to 2007 he served as the German Business
Delegate in the United Arab Emirates, Oman and Qatar, based in
Dubai. The Ministry sent him to Washington D.C. for two years in
1998, as Political Economic Envoy to the office of the German
Business Delegate; in 1999 he took over as Acting Director of this
office, representing the Federation of German Industries and the
German Chamber of Commerce in the USA.
From 1988 to 1997 he was an energy policy consultant in the
Federal Ministry of Economics and Technology in Berlin.
Dr. Friedrich is a Doctor of Engineering from Clausthal University.
Kirsten Bay is redefining what it means to be a fearless leader in the technology industry, let alone an accomplished, bilingual, female executive, transforming the cyber security space. As President & CEO of Cyber adAPT, she leverages more than 25 years of experience, leading her team with risk intelligence, information management, and policy expertise across a variety of sectors.
Throughout her career, Bay has been appointed to a congressional committee developing cyber policies, initiatives and recommendations for the intelligence community, developed recommendations in partnership with the Center for North American Studies (CNAS) and Center for Strategic and International Studies (CSIS) for The White House energy policy, collaborated on information studies for MIT-Harvard and several federal agencies, gone before a parliamentary subcommittee on recreating trust in the global economy, presented national security and critical infrastructure concepts at conferences such as Black Hat, Secured Americas, Enterprise Architecture Institute, SC World Congress, & The Eurim Information Management Committee, and has spoken on applied economics and its relationship to both cyber and national security around the world. Bay is a self-proclaimed ‘serial student’. Her current membership in the Alliance of Chief Executives feeds that perpetual drive to learn and share insight with peers, an inspirational trait she models for her Cyber adAPT team.
In previous Executive roles for ISC8, Attensity Group, and iSIGHT Partners, Bay led the companies through corporate restructuring, risk & corporate intelligence product launches, and company turnarounds, respectively.
With a BA in English and German from the University of Oregon, let’s just say she will correct your grammar in multiple languages.
Professor Klaus Josef Lutz has been the CEO of BayWa AG since 2008 and is responsible for Internationalisation, Risk Management, Corporate Business Development, Marketing, PR/ Corporate Communications, Internal Audit, the International Agriculture Division and the Fruit Division.
Born in Munich, Klaus Josef Lutz studied law at the Ludwig-Maximilians- University in Munich. He began his career as a lawyer but soon assumed leading positions in various industries, in the course of which he acquired extensive expertise in restructuring and developing companies.
Among others, Lutz held positions as Managing Director of Digital Equipment GmbH, CEO of DITEC Informationstechnologie AG, CEO of Burda Druck GmbH, and CEO of i-center Beteiligungen AG. Immediately prior to becoming CEO of BayWa AG, Lutz was Managing Director of Süddeutscher Verlag GmbH, one of Germany’s largest media groups.
Lutz has served as CEO and Chairman of the Executive Board of BayWa AG since July 2008. BayWa is a trading and services group with international operations. Its core businesses are agriculture, building materials and energy, with a special focus on renewable energies.
Furthermore, Klaus Josef Lutz holds positions in the Supervisory Boards of many listed corporations and private companies, including Euro Pool System International, Rijswijk/ Netherlands (Chairman), WHG mbH, Klagenfurt/ Austria (Chairman), Turners & Growers Ltd., Auckland/ New Zealand (Chairman), RWA AG, Vienna/ Austria (Member) and Giesecke & Devrient GmbH, Munich (Chairman). Additionally, he is Vice President of the GermanRaiffeisen Association and Vice President of the Chamber of Commerce for Munich andUpper Bavaria.In 2013, Lutz was named Honorary Professor by the Technical University Munich for theFaculty Managerial Economics of Co-operative Societies.
Klaus Peter Kofler – known affectionately as KP – comes from a family with a long and distinguished tradition in food that stretches back to the foundation of Kofler Bakery in 1823. He is the sixth generation to have learned the trade of baker and graduated as the best in his year. In 1988 KP added a very contemporary qualification to his “hereditary” culinary skills when he graduated in business studies.
In 1991 KP Kofler took yet another decisive step by ending his career as a professional showjumper in order to give his undivided attention to his new business: Kofler & Kompanie.
As a true entrepreneur, KP Kofler is a master in reflecting and seizing the zeitgeist. In 2008 Kofler was named “Restaurateur of the Year” by Gault Millau. Perhaps his most offbeat creation is Pret A Diner, a much-lauded series of pop-up restaurants that have appeared for a short time in Berlin, Frankfurt, Munich, London and Zürich and create quite a stir with Michelin-starred chefs, sophisticated cocktails, contemporary art and modern music in offbeat locations with hip themes.
In addition, Pret A Diner pop-ups always boast the top chefs from the culinary scene. These have included Nuno Mendes from the Viajante, Matthias Schmidt from the Villa Merton, Juan Amador with his eponymous restaurant and the “King of the Italians” Giorgio Locatelli.
KP Kofler firmly believes that he must convince his guests with his food right from the outset: “With our food we strive to create an event at an event. And it is not just the ingredients that play a role – presentation, ambience, service, decor and sensory qualities must also be perfectly harmonised so that a feeling of supreme pleasure can evolve. Completely in keeping with our “Satisfying all Senses” motto.”
Luke Minford is Chief Executive of global IP consultancy, Rouse, which has 13 offices in 17 countries and a strong focus on Asia and emerging markets.
Luke has a wide range of experience dealing with IP strategy and protection in Asia, particularly the People’s Republic of China. He advises on a wide range of intellectual property issues encompassing technology, brand and content rich companies. Luke is consistently ranked as one of the world’s leading IP strategists and speaks regularly around the world on the subject. One of his passions is China, where he has lived, worked and studied for more than 25 years. He speaks Mandarin fluently and is currently based in Beijing, China, from where he oversees the running of the group.
As founder of VIM Group, Marc has been responsible for its global expansion and for developing the business into a leading brand implementation and management consultancy – working with a range of clients, from well-known multinational companies representing a variety of sectors, to non-profit organisations. Marc is author of Future Proof Your Brand – a best seller book on Amazon, and he is an accomplished speaker and blogger on various global platforms.
He is also ambassador of the working group on Brand Leadership of the European Association of Communication Directors, a member of the advisory board of Communication Director magazine, a non-executive director of the leading brand valuation firm, Brand Finance, and a member of A.W. Page Society. Out of offices in London, Amsterdam, Frankfurt and Munich a wide array of clients are served.
Clients include Deutsche Telekom, ABB, IKEA, DNVGL, ING Group, SkyTeam, Schroders, Air Liquide, Merck, BMW, Danfoss, Skoda, Medtronic and Julius Baer Bank. Marc spends his private time with his wife and three children. He is an active mountain biker around the beautiful Dutch countryside – although there are no mountains.
Marcel Inäbnit graduated from Universität St. Gallen (HSG) in Switzerland and has gained in his career a wide experience in marketing and sales management of various consumer goods in the non-food, food and hospitality industry.
Today, Marcel is managing several companies as MD or Co-CEO inside ROTHO Group which is one of Europe’s leading manufacturers of plastic consumer goods (housewares and office supply) with production sites in Switzerland, Poland and Italy. In 2015, based on a business plan Marcel developed together with his team, he has got the responsibility for a start-up inside ROTHO Group. The Italian AALTA srl specializes in the production of medical waste containers mainly for the disposal of sharps. AALTA operates and produces near Venice.
Before joining ROTHO, Marcel Inaebnit was working for a couple of years in the hospitality industry. As Director of Sales and Marketing of the Swiss based Victoria-Jungfrau Collection – at that time two 5-star hotels and member of Leading Hotels of the world (LHW). His career in marketing Marcel started in KNORR (part of Unilever) where he was Junior PM for ready dishes.
Marc L. Hoffman, M.D. is Chief Medical Officer at Celerion Inc., a global, full-service, mid-size Contract Research Organization (CRO) with an emphasis on early clinical development. The Chief Medical Officer is a key leadership position at Celerion, directly involved in defining and implementing the overall business strategy and direction of the organization. This position provides medical oversight, expertise and leadership to support early clinical research studies at Celerion’s clinics globally as well as operational responsibility to oversee and expand clinical operations focused on early clinical research (phase I/II) performed outside of Celerion clinics in North America. The Chief Medical Officer will act as a safety medical expert and serve as a subject matter expert within a cross-functional, multi-skilled team environment involved in helping Celerion’s clients navigate the complexities of performing early clinical research in human populations. Dr Hoffman brings with him thirty years’ experience as a pharmaceutical physician in various roles. Dr. Hoffman joined Celerion from Patient iP, a healthcare technology company focused on patient recruitment solutions, where he served as Chief Medical Officer and Chair of their Scientific Advisory Board, providing clinical leadership around Patient iP’s innovative platform, customer programs and related medical affairs activities. Prior to joining Patient iP, he held the roles of Chief Medical Officer and Senior Vice President and General Manager over the Biopharmaceutical Business at Theorem Clinical Research, leading the development of drugs and biologics. Previously in his career, Dr. Hoffman held positions of increasing responsibility in Medical and Scientific Affairs at Baxter, Hospira and Covance, providing senior-level strategic direction for Phase II-IV programs. In addition to his medical degree, Dr Hoffman has a Diploma in Pharmaceutical Medicine.
Marcus W. Mosen, 20+ years experience in senior executive functions with leading companies in the telecommunications and payments sector, e.g. First Data, easycash and ogone. In 2013 Marcus joined Concardis as Chief Operating Officer. In 2015 he took over the CEO function at Concardis, the leading full-service payment provider in German-speaking Europe. Marcus is also engaged as advisor and non-executive director in payment start-ups like orderbird, a supplier of iPad based cash register systems for gastronomy. He is also an author and editor of publications on the topic of cashless payments.
Mario has a proven track record in the healthcare sector. With 20 years of experience in developing and implementing innovations for health insurances, physicians’ associations and innovative pharmaceutical and medical device companies, Mario brings profound expertise and leadership to the team. Mario holds a medical doctorate from the University of Hamburg and an MBA from Erasmus University in Rotterdam, Netherlands.
Mr. Matthew Robin has been the Chief Executive Officer of Elsa & Mifroma group at Migros-Genossenschafts-Bund since April 2011. Mr. Robin served as an Executive Officer of Injection Systems at Disetronic Holding AG. Mr. Robin served as Senior Vice President and Head of Business Unit Liquid Handling and Robotics of Tecan Group Ltd. since February 2007. He served as Chief Executive Officer of Ypsomed Ag from 1998 to 2006. He served various positions in production, marketing, sales and general management for Lonza AG in Switzerland and USA from 1987 to 1998; Burgdorf from 1998 to 2000; Divisional Head of Disetronic Injection Systems at Disetronic, Burgdorf from 2000 to 2003. From 1987 to 1998, he served at Lonza Fine Chemicals, various functions in the USA and Switzerland, lastly served as Business Director for US Custom Manufacturing. He served as a Divisional Head of Liquid Handling & Robotics of Tecan Holding AG since 2007. Mr. Robin has been a Non Executive Director of COLTENE Holding AG since 2006. He serves as Non Executive Director of Medisize Holding. He serves as Member of Advisory Board of BV Holding AG. Mr. Robin holds M.Eng Degree in Chemical Engineering from Imperial College, University of London.
Max Gruenig is the President of Ecologic Institute US and has been with Ecologic Institute since 2007. His work focuses on sustainable development in the energy and transport sector, as well as urban sustainability and resilient cities. In particular, he is leading the efforts by Ecologic Institute in the Emerging Leaders in Environmental and Energy Policy Network (ELEEP). He is also coordinating the Post-Carbon Cities of Tomorrow (POCACITO).
In 2004, Max Gruenig received his degree in economics from the Humboldt-Universität zu Berlin (HU Berlin, Germany). The main focus of his studies was natural resource economics and auction theory.
Max Gruenig has lived and worked in Germany, the United States, Iceland, and Japan. He is a native speaker of German and is fluent in English and French. He is a founding member of the European Institute for Sustainable Transport (EURIST), a member of the sustainability advisory board for NaturEnergiePlus and a member of the Consumer Research Network run by the German Federal Ministry for Justice and Consumer Protection (BMJV).
Lombardi, P., Gruenig, M. (Eds.) 2016: Low-Carbon Energy Security from a European Perspective, Elsevier Academic Press.
O"Donnell, B., Gruenig, M., Riedel, A. (Eds.) 2017: Arctic Summer College Yearbook - An Interdisciplinary Look into Arctic Sustainable Development, Springer Nature.
Mayukh Sukhatme, M.D. has served as Chief Business Officer of Roivant Sciences, Inc. since November 2016. He previously served as Roivant’s Senior Vice President, Business Development from April 2015 to November 2016. From 2000 to 2015, Dr. Sukhatme was a healthcare-focused analyst and Portfolio Manager for large institutional investment firms, including both public markets and venture capital firms. His principal focus was on development-stage biotechnology and pharmaceutical companies, where he led diligence and investment decisions on numerous companies and pharmaceutical compounds across a wide variety of therapeutic areas. Most recently, he was a partner at Apple Tree Partners, a healthcare venture fund. Dr. Sukhatme received his M.D. from Harvard Medical School and Bachelor of Science degrees in Biology and Literature (Phi Beta Kappa) from MIT.
Dr. Nadav Navon has been at Intec Pharma since March 2006 and since March 2015 serves as Executive Vice President of Research & Development and Operations. Before that he served as Intec’s Vice President of Research & Development and Operations since May 2013. Prior to his service with Intec, Dr. Navon headed the analytical and quality assurance operations at Sharon Laboratories Ltd., a chemical company that develops and manufactures raw materials for the pharmaceutical, cosmetic and food industries, from 2001 to 2006. Prior to that, Dr. Navon led a number of research and development projects in the Negev’s Nuclear Research Center. Dr. Navon has a Ph.D. in inorganic and analytical chemistry, and an MBA and a BSc in chemistry, each from Ben-Gurion University in Beer-Sheva, Israel.
Najeeb Ghauri is the founder, Chairman of the Board of Directors and CEO of NetSol Technologies, Inc. "NetSol", a U.S. corporation providing global business services and enterprise application solutions to private and public sector organizations worldwide. In the early years of the Company, Mr. Ghauri was responsible for restructuring the company's business model into that of an IT company and was instrumental in the completion of the NetSol Technologies IPO in 1998, at that time NetSol was the first IT Company with operations in Pakistan to be listed on NASDAQ. He also spearheaded the successful listing of NetSol (NTWK) on the NASDAQ Capital Market (formerly known as Mirage Holdings, Inc.) in December 1999.
NetSol grew from just five people to 1,800 employees worldwide. NetSol Pakistan Ltd., a subsidiary of NetSol Technologies, Inc. has over 1500 programmers and engineers in Lahore and Karachi offices. NetSol revenue grew $100K revenue in 1998 to $65MN in 2016 and tracking $100MN by 2017. NetSol has a global footprint with subsidiaries in Pakistan, US, UK, China, Thailand, Germany, Australia and Saudi Arabia. Today, NetSol has nearly 300 plus customers worldwide mostly fortune 500 companies.
Mr. Ghauri was also instrumental in listing NetSol’s Pakistani subsidiary on the Karachi Stock Exchange (KSE). In addition, Mr. Ghauri helped establish the first U.S. company listed on both NASDAQ Capital Market (NASDAQ CM: NTWK) and (NASDAQ DUBAI: NTWK).
Mr. Ghauri represented NetSol as he presided over ringing of the bell ceremonies several times on the NASDAQ Exchange platform in New York City. He has been twice nominated in the United States for the Ernst & Young 'Entrepreneur of the Year', once in 2001 and again in 2008.
Prior to launching NetSol in the U.S., Mr. Ghauri had over 15 years of combined marketing and management experience with Fortune 500 companies such as Unilever and Atlantic Richfield Corporation (ARCO). He received his bachelor's degree from Forman Christian College, a B.S from Eastern Illinois University and earned an MBA in marketing from the Drucker School of Management at the Claremont Graduate School, Claremont, California.
Mr. Ghauri is also active in various charitable and educational non-governmental organizations (NGOs) worldwide. He is a founding board member of the Pakistan Human Development Fund, which provides educational tools to children in underdeveloped areas of Pakistan. He is also a founding board member and is a former Vice-Chairman of the U.S. Pakistan Business Council in Washington, D.C., a U.S. Chamber of Commerce body and the leading private sector association in the United States promoting trade and investment between the United States and Pakistan.
Mr. Ghauri is a Pakistan born US citizen. He is based in NetSol Technologies Headquarters in Los Angeles, California and Lahore, Pakistan simultaneously.
Effective on January 1, 2015, Nataline was named CEO, although she has played an integral role in Giroux Glass’ financial strategies in each of her previous roles as Treasurer, then Controller and most recently, as CFO. Since 2002, Nataline has been responsible for all financial aspects of the company, including financial and risk management operations. Prior to Giroux Glass, she worked in the Construction Industry in finance and accounting roles for over 24 years, mostly within executive management roles. Nataline has served as Controller to large corporations as well as run her own small business, all of it adding to her wealth of valuable Industry expertise. Nataline has played a pivotal role in the success and growth of Giroux Glass, as an inspirational leader and as the driving force behind transitioning Giroux Glass to full employee-ownership. She holds a Bachelor’s degree in Finance from California State University, Fullerton.
With 15 years of experience in operational and strategic management within the pharmaceutical industry, Mrs. Ouzren started out at Baxter, where she was Strategy and Operational Excellence Manager, Quality Operations Director and Senior Director Strategy before becoming Vice President of the BioSimilars business unit. In 2014, she became Vice President of the Global Hemophilia Franchise at Baxalta, which had been incorporated within the Shire group. In 2016, she headed up the Global Genetic Diseases Franchise at Shire, where she supervised all marketing, business and strategy aspects of this global division’s product portfolio.
Nick acquired David Phillips in 2005 and became CEO thereafter. Since then, David Phillips has grown revenues and profits with CAGRs of 28% and 25%. It is now the leading specialist furnishing company servicing the Residential and Social Living markets in the UK, and increasingly, across Europe. Prior to joining David Phillips, he set up Winghaven Partners and previously was an investment banker with Rothschild and JP Morgan in London, New York, Latin America and Hong Kong and speaks Spanish and Portuguese.
Offer Fabian is a veteran entrepreneur with over 25 years of experience the last 9 of which in the bio-tech industry. Offer is co-founder and CEO of Musli Thyropeutics a clinical stage pharmaceutical company developing a fixed-dose combination for the treatment of
a variety of cancers based on a novel hormone deprivation approach. Musli’s mechanism of actions has been validated in clinical studies, and the patented combination is being successfully used for compassionate treatment of patients with Glioblastoma Multiforme (GBM) and other indications. In pre-IND discussions with the FDA, the company received a green light to advance in the clinical track, and is currently raising capital for phase II and III trials.
Prior to founding Musli, Offer was VP Commercial development for Insightec, maker of MRI-guided focused ultrasound medical device, working with a global team to increase adoption of this novel treatment approach. Offer was also co-founder and co-CEO of Medial Research a big-data company which developed ColonFlag - a population screening algorithm identifying individuals at high risk which is already commercially used today. Offer holds an MSc from Tel-Aviv University in computer science.
Before starting at AFFiRiS, Oliver Siegel headed the pharma practice at Rothschild
Investment bank in London, where he previously also worked as Head of European
Pharmaceutical Sector. He advised Roche in multiple MNA and financial transactions, for
example at the acquisition of Genentech. He also supervised the IPO of several top-class
companies like Serono or Speedel. Prior to this, he was Head of Healthcare Investment
Banking at HSBC plc. in London.
Paul has over 25 years’ experience in senior leadership roles within the Health and Protection consulting market. Over the last 20 years he has been a main board Director with a number of advisory organisations.
Paul's responsibilities include delivering organic and M&A growth for all of the companies that make up Punter Southall Health and Protection Holdings. He has a specific focus on wellbeing within the workplace and the role that technology can have in transforming the employee benefits market.
In addition Paul is Non-Executive Chairman of Loopeeze Limited, a start-up venture which has recently successfully completed its first round of fund raising to support the global distribution of FabLittleBag which aims to revolutionise women’s experience of sanitary disposal.
- more than 12 years’ experience as Managing Director and COO as well as General Counsel of stock listed (TecDax) companies
- with more 40 professionals
- departments in EMEA, Americas and Asia-Pacific
- 8 years Leading Professional Services Organizations
- Expertise in managing KPI driven High Performance Teams
- Operational Responsibility for Best Practices and Compliance Methods
- Excellence in all operational Service Functions
- Management Reporting with ERP and BI Systems (SAP, Sage, AX)
- International working Style and Hands-on Engagement
- Responsible for a global budget of more than € 20 Mio.
- Expertise in Corporate Compliance
- Project-Leader for national and crossborder M&A transactions
- Member of the German Corporate Compliance Forum, Frankfurt
- Current Position: COO and Member of the Executive Board of Thinkstep AG, Stuttgart
- Business Operations & Order Entry
- Finance & IT
- M&A Strategy and Execution
- KPI Management Reporting
- Legal & HR
- International Subsidiaries – Controlling & BI Reporting
- 2010-2014: Managing Partner of Alegis GmbH - Professional Services,
- LPO (Legal Process Outsourcing)
- Transaction Services M&A
- Sales Operations & Delivery
- Treasury Management
- Payment Factory and Corporate Bank
- IP Licensing - Luxemburg
- Shared Services
- 2000-2009: Head of Corporate Development & Legal, IDS Scheer AG
- Managing Director IDS Scheer Finance, Luxemburg
- Managing Director IDS Scheer Turkey
- International Contract Management
- Corporate Compliance-officer
- Corporate HR
- HR Development
- HR Administration
- HR Communication
- Post-Merger Integration
- Corporate Development - M&A Project Leader
- Acquisition Balink AG, Suisse
- Acquisition Business Logica, Russia
- Acquisition Group Enel, Croatia
- Acquisition Plaut AG, Austria
- Acquisition Bristlecone Inc, USA, Cal.
- Acquisition Acqra Solutions, USA, Phil.
- Acquisition Radermacher GmbH, Berlin
- Acquisition and Merger IBCS SA, Lux.
- Joint Venture IDS Scheer CEE ./. Procont, Hungary
- Acquisition FACT GmbH, Frankfurt
- IDS Scheer Venture Capital GmbH
- 1996 – 1999: Ferrostaal AG, Essen / DSD Dillinger Stahlbau GmbH:
- International Contract - management:
- River Tagus Bridge Lisbon
- Power Plant Malaysia
- Transrapid: Legal Project Team
- Legal Counsel in Subsidiaries: Malaysia; Portugal, Sweden, Spain & Italy
- PhD at University of Cologne, Law School (June 2008): „Riskmanagement- systems in Capitalmarket-Compliance“
- Kellogg Graduate School for Management & Northwestern University, Chicago, WHU Wissenschaftliche Hochschule für Unternehmensführung, Koblenz Executive MBA (Kellogg/WHU) 30.09.2001
- University Saarland, Law School:
o State Examination 02.07.1993
o State Examination 31.01.1996
- Tulane Law school, New Orleans, LA
Languages: English (fluent), Spanish (fluent), French
o BITKOM AK Compliance
o Finance Roundtable Corporate Syndici,
o Bundesverband Mergers and Acquisitions e.V.
o inPraxi-Alumni - WHU, Kellogg-Alumni – NWU/Chicago
o Legal bar, OLG Saarbrücken
Having started as a consultant, followed by being the CEO of a medium-sized company with 250 employees up to today as a Founder and and Managing Director of digital consultancy and company builder etventure, Philipp Depiereux is employed with innovation projects. He founded etventure together with two partners, following the vision of combining the experiences as entrepreneur and innovation driver in the mid-size sector, in the corporate world as well as in startups and digital projects in
Silicon Valley within one company.
Rainer Klee, Chairman of the Management Board of AERTiCKET, has been shareholder and CEO of AERTiCKET AG from its foundation in January 2002 until 2016. Previously he was the Managing Director and founder of the predecessor company AER Reiseservice for nine years.
Rainer graduated in business studies from the University of Mannheim in 1980 and then worked in several areas of business in Berlin, mainly as a freelancer and with other entrepreneurs. In 1988 he and five friends and acquaintances set up the travel agency “Titanic Reisen”. The consolidator AER Reiseservice was founded in 1993 as a “Spin Off” of Titanic Reisen, which remained for many years as a shareholder of AERTICKET later. Today the shareholders of AERTICKET are Rainer himself and the cooperation AER - a cooperation of more than 1000 travel agencies, which is the majority shareholder. Rainer has completed several further vocational training courses, including as a coach and facilitator. From the beginning of 2009 until the end of 2012 he has spent around half his time working in the USA as CEO of Picasso Travel Picasso Travel, a subsidiary of AERTiCKET.
With his deep knowledge of the Consolidator as well as Travel business Rainer is continuously driving the competitive position of AERTICKET on a global scale.
Rainer Koppitz is Chief Executive Officer and a member of the Management Board of B2X, the leading technology provider of customer care solutions for smartphones and the Internet of Things (IoT) with operations in more than 100 countries. He leads the company’s more than 800 employees and the global customer care ecosystem with more than 400 trusted service partners in executing B2X’s vision and strategy to keep people online and minimize the disruption of their digital lives.
Rainer has more than two decades of experience in business technology with significant expertise in Software as a Service (SaaS), Business Process Outsourcing (BPO) and Customer Care. As an international business leader, he has a proven track record in leading both startup companies and large international organizations in the technology and telecommunications industries. Rainer’s responsibilities at B2X include Strategy, Operations, the SMARTCARE Technology platform, Sales, Marketing and Investor Relations.
Rainer launched his business career at Siemens and held management positions in thriving technology companies, including CEO at NFON, a venture capital backed leading provider of high-end telephone systems from the cloud, and Vice President and General Manager of Dell’s service division in Europe, Middle East and Africa. Rainer joined B2X from British Telecom where he served as CEO for Germany and Austria.
Ralf Hertneck studied physics and is self-employed in the IT environment since 1997 operates. In 1999 he founded to offer the current system house Anywhere.24 Technologies GmbH and 2001 InfoAnywhere.24 with the aim outstanding services in the CRM environment. From this the Anywhere.24 emerged GmbH 2005 to round out the solution and service portfolio. He is responsible for strategy, sales and project management.
Ralf Reichert is a man who has lived by his moto, “cut your own path”. A former soccer-player for Rot-Weiß Oberhausen, the athletic young man turned to eSports with his brothers and friends to found the now world-renowned clan, SK-Gaming. Constantly pushing at the boundaries of what is possible, Ralf’s vision of what the industry could (and should) be, is what has gotten the company so far. As a passionate gamer himself, he is constantly striving to put eSports up there alongside ‘traditional’ sports.
Managing Director / CEO
Turtle Entertainment GmbH
2000 – Today
Member of the Board
GIGA Television GmbH
2006 – 2007
1997 – 2001
Assistant to Managing Director
1994 – 2000
RK, currently serving as CEO & Chairman of Rheinhold & Mahla Group, is a German manager with an British/Indian ancestry. Having lived, worked and lead organisations in Americas, Europe and Asia, he has a good command of multiple linguistic, cultural and leadership aspects across.
RK, holds a twin masters in engineering and economics from TU, Karlsruhe, Germany, executive leadership specialisation in LBS and Insead. Before he took the helm at R&M group, he served in leadership positions in Siemens for 17 years, formerly leading the global automotive vehicle electronics as the Managing Director of the Division. Currently, RK is one of the major shareholders of R&M, also serves in select Boards of Tech & Industrial Investments, especially for Mid-Cap PE investments.
RK business profile demonstrates constant focus on profitable, sustainable business expansion with portfolio restructuring and market positioning. His industrial focus lie first tier Automotive Suppliers, EPC Solutions, and "click & mortar" innovations (encompassing German "Mittelstand")
RK resides in Munich, spends his free time with his family on plantations, astronomy, cooking and guitars.
Rami founded Telesofia Medical (MyOp.md), combining his passions to medicine and technology.
He has over 20 years of experience in the Internet industry. He started his career in 1997 at ICQ (formerly Mirabilis, acquired by AOL in 1998, for US$407 million) in various roles including Director of Web Operations. Since 2001, he helped several companies and start-ups with product development, launching and marketing in the online world. As VP Operations at Novawind, he provided Hands-On marketing, business development, and innovation management services for leading companies.
Rami also holds a medical doctor degree from the Tel Aviv University and worked at the Vascular Surgery department in Tel-Aviv Sourasky (Ichilov) Medical Center and Assaf Harofeh Medical Center.
Ramin is responsible for strategic management and business model development at FinLeap. He consulted 20+ international banks and was Lead Innovation Manager at DKB. He is an Entrepreneur and Angel Investor and holds a degree in Business Information Systems
Ricardo Oliveira Nobre, CEO of Cross Border Talents Group is an expert in the context of talent mobility and world of work matters. Ricardo has a master degree from a European top-tier university (Mechanical Engineering, IST) and is the former Strategic Clients Director and Board Member of an American company in Germany (650 mn. € in revenue and 20.000 employees).
Ricardo has 20 years management experience in engineering, recruitment and ICT training. He started his career at ABB Alstom Power, where worked as Engineer Site Manager in Portugal (Alqueva Mutlipurpose Dam, largest artificial lake in Western Europe) and Thailand (Lam ta Khong pumped storage Project). He joined the recruitment industry in 2001, having worked 13 years as country manager and international business concept developer across 44 countries for a world top-tier staffing company. In 2014 Ricardo founded Cross Border Talents, a Horizon 2020 SME Instrument Champion. His ambition is to contribute to solve the global skills shortage challenge through consistently facilitating employment transitions in increasingly volatile and complex labor markets. Ricardo is a member of the Digital Skills and Jobs Coalition (European Commission). In 2016 his project proposal CBT Academy (a disruptive business model to recruit, train and employ 500,000 ICT Professionals by 2020) was awarded with Seal of Excellence, a certificate delivered by the European Commission as the institution managing Horizon 2020, the EU framework programme for Research and Innovation 2014-2020.
Ricardo married Marta in 1998 and is father of Ricardo, Frederico and Rita.
Prof. Sahin Albayrak is a professor of computer science and holds the chair Agent Technologies in Business Applications and Telecommunication (AOT) at TU Berlin. He is the founder and head of the Distributed Artificial Intelligence Laboratory (DAI-Labor) at TU Berlin, currently employing over 100 researchers. He is also the founder of Deutsche Telekom Innovation Laboratories, and the founding director of the Connected Living Association and the German-Turkish Advanced Research Centre for ICT (GT-ARC). He serves as an advisor to several government authorities and large scale companies in both Germany and Turkey. His research interests include smart cities, intelligent mobility systems, next generation telecommunication services, smart energy systems, agent-oriented modeling, and autonomous security.
Scott Myers is President, Chief Executive Officer and Director of Cascadian Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing innovative product candidates for the treatment of cancer. Prior to joining Cascadian Therapeutics in April 2016, Scott served as the Chief Executive Officer of Aerocrine AB, a life sciences company until it was acquired by Circassia Pharmaceuticals plc in July 2015. Prior to Aerocrine, Scott served as a Vice President of UCB S.A., a Belgium-based biopharmaceutical company where he was responsible for commercial operations and medical affairs for 32 countries in Europe. Earlier in his career, he served as the Chief Commercial Officer for DOV Pharmaceutical, a development stage pharmaceutical company, and held several senior positions at Johnson & Johnson, including Senior Vice President and General Manager. Mr. Myers received his B.A. in biology from Northwestern University and M.B.A from the Graduate School of Business of the University of Chicago.
Dr. Sella Brosh is the Chief Executive Officer of NVision
Imaging Technologies, a spinoff company from the institutes
of Quantum Optics and Theoretical Physics in the University
of Ulm, Germany. NVision leverages new advances in
quantum physics to disrupt the cancer imaging space by
enabling standard MRIs to visualize areas of high metabolism
typical of cancer (market currently dominated by the
radioactive, expensive and clinically limited PET/CT imaging
modality). Prior to joining the leadership team of NVision, Dr.
Brosh worked as senior engagement manager at the US
mid-atlantic office of McKinsey & Company. He led multiple
global commercialization efforts in the Pharma and Med
Device spaces and worked alongside Market Access and
R&D teams of top-10 players to optimize their early pipelines
and structure a value driven approach. Prior to his career in
the healthcare industry he served as a combat engineering
officer, first as platoon commander and later as an officer of
operations of a combat battalion. He received his Bachelor of
Medical Science (magna cum laude) and Medical Doctor
degrees from Tel-Aviv University.
The latest wave of digital disruption is transforming industries. As digital technologies such as Cloud, Analytics, Mobile, Social, and the Internet of Things gain momentum, they are altering market structures and business models. I believe digital capabilities increasingly, will determine which companies create or lose value. At Marlabs, we partner with clients to capture the growth opportunity offered by digital. We prioritize client satisfaction over everything else and our focus on speed and innovation is our differentiation. And importantly, we are of the right size, which means we are large enough for our clients’ comfort and small enough to be nimble. Leveraging our extensive technology and domain expertise and high performance teams, we deliver innovative technology solutions and services that help clients meet their IT and business challenges.
After graduating in mechanical engineering from the University of Hanover, Dr. Stefan Franzke became managing director at the Institut für Integrierte Produktion in Hanover. As the head of the Innovation Center Lower Saxony beginning in 2003, he intensified his know-how in in the field of strategy consulting for innovations and key technologies and advised international investors in their relocation process. Additionally as the managing director of Innovatives Niedersachsen, he was responsible for the national and international marketing of the federal state starting in 2006. Since July 1, 2014 Dr. Stefan Franzke is the CEO at Berlin Partner for Business and Technology.
Dr. Stefan Wess holds a PHD in Artificial Intelligence and is CEO of Empolis Information Management, a IT company that utilizes cutting-edge Artificial Intelligence methodologies for their software to assist users with their decision-making or digital assistants that support them.
His professional career includes roles as the technical manager of the U.S. AI-provider Inference Corp. (acquired by eGain Inc.). He was Executive Board Member of tecmath AG (acquired by Avid) and Managing Director of tec:inno GmbH. From 2000 to 2008, Dr. Wess was CTO and later CEO of a subsidiary of Bertelsmann arvato AG in Gütersloh, Germany and managing director within the arvato group. He later became a member of the Attensity Group management board, based in Palo Alto, out of which Empolis Information Management GmbH was spun off as an independent company in 2012.
Consequently, he is often consulted as a recognized high-tech expert on artificial intelligence. Dr. Wess is an acclaimed speaker and author on Artificial Intelligence and has had the honor to speak at the TEDx 2014 and at other international forums, where he gives insight into the exciting world of tomorrow. Stefan is a member of the DFKI (German Research Center for Artificial Intelligence) Board of Directors, as well as for RS Media in Duesseldorf, Germany and Trustee of the Fraunhofer Gesellschaft.
In his free time, he is a passionate motorcyclist and still remains a computer nerd at heart…
Steve King is the CEO and Co-Founder of Black Swan, the fastest growing start up in the UK, which combines cutting edge data science and software development to accurately predict trends in consumer behavior. Since reading Cognitive Science the 90s, Steve has applied his tech, coding and visualization skills to solving his clients’ challenges, helping them work out what will be important tomorrow by arming them with products that transform the way their brands create value from data. Black Swan works with some of the world’s leading consumer-faced brands including PepsiCo, Panasonic, npower and Disney.
Stuart Rose founded The BioScience Center in Albuquerque in 2012. Dr. Rose is a serial entrepreneur with more than four decades in the pharmaceutical manufacturing industry and the host of more than 20 startups developing vaccines, medical devices and research tools. His most recent endeavor is PaizaBio, a joint venture with a Chinese partner. China represents an unparalleled growth opportunity for Western pharmaceutical companies. While its not uncommon for Western companies to have a manufacturing presence in solid and oral drug manufacturing in China, the aseptic injectables market has remained elusive, restricted to imports and leaving the market untapped for domestic sourcing. This need resulted in the partnership and PaizaBio. In 2014, Dr. Rose also opened FatPipe ABQ as a privately funded collaborative work space providing amazing internet bandwidth speeds, program and training for entrepreneurs, and his advice and guidance to any startup that asks for it. Stuart's approach to supporting the entrepreneurial ecosystem is unique. He believes the private sector needs to take the lead and has proven so by investing in his city's startup culture.
Szabi is the CEO of Turbine, a team of AI researchers,
biologists and medical doctors simulating the inner workings of cancer cells.
Turbine's goal is to transform the way drugs are tested
and discovered. By digitalizing the trial and error part of research that takes years with biological experiments, the team is working to get better drugs to patients, faster.
Balance Integration Corporation Founder/CEO Tevis Trower is a pioneer in optimizing corporate cultures. Heralded in bestselling Megatrends 2010 as “corporate mindfulness guru for the new millennium”, Tevis has assisted powerful organizations ranging from Disney to Morgan Stanley in optimizing their most precious assets: human beings. Serving clients in over 70 US markets, Europe and Latin America, Balance Integration has provided global executive immersions for prestigious organizations including Harvard Business Review Events, Young Presidents Organization, PWC, KKR, Soros, Bloomberg LP, Viacom, Google and The Economist on issues including mindfulness, executive lifestyle, personal mastery, innovation, and the role of consciousness in creating radical success. You can find profiles and expert advice from Tevis featured in respected media outlets including Forbes, Fortune, BusinessWeek, Glamour, YogaJournal, CIO, Pink, RealSimple, Crain’s, New York Post, Financial Times, WWD, New York Observer, MSNBC, FoxBusiness, NY1 and Martha Stewart. As NYU Faculty teaching Business Creativity & Personal Mastery, Tevis has also served as worklife expert to WebMD and Huffington Post. Tevis lives what she teaches from her home in Woodstock, enjoying surfing, snowboarding and entertaining friends at home with her little doggy, Ruby.
Based in Dresden, Germany, Thibaud Le Séguillon is currently CEO of Heliatek GmbH, a high-technology startup in the OPV-Organic Energy field. Heliatek is a global leader in OPV technology utilizing small molecules (oligomers). The light-weight, flexible and optionally transparent solar films provide clean solar energy wherever it's needed.
Mr. Le Séguillon was previously based in Shanghai, China, where he was the President of Parlex Corporation, a 1500-employee, $100MM worldwide leader in flexible interconnect that is part of the Johnson Electric Group. The company had engineering centers in the US and Europe, two manufacturing sites in the US, and manufacturing sites in China and in the UK.
Previously, Mr. Le Séguillon was Vice President of a Business Unit of Parlex. He led a worldwide business development & engineering team and led direct sales efforts focusing on key customers and contract manufacturers in consumer electronic, medical, automotive and smart card industries. Additionally, he played a key role in restructuring plants in Mexico, the US, and China, and redeploying product line manufacturing.
Prior to working in China, Mr. Le Séguillon worked in Boston, MA, for Parlex Corporation (NASDAQ: PRLX) as Vice President of Operations, where he was in charge of engineering, quality, HR, materials, logistics, and customer functions for two manufacturing operations. He also oversaw a manufacturing site in Mexico.
Earlier in his career, Thibaud advanced in product engineering, sales engineering, and product marketing management roles to the position of General Manager at Axon’ Cable Inc., a subsidiary of Axon’ Cable SA, based in Chicago, IL.
Mr. Le Séguillon is a Board Member of AETS-ESEO, and a French Trade Counselor, Conseiller du Commerce Exterieur de la France. Mr. Le Séguillon has an MBA in International Business from NEOMA-Reims and a Master of Science in Engineering from ESEO.
Dr. Thomas Henkel is CEO and co-founder of TARGOS Molecular Pathology GmbH, Kassel, a company focussing on research and development services regarding clinical biomarkers and targeted therapeutics. Targos was established in 2005 and since then has developed in one of the premium service providers in the field. He also serves as acting CEO of the daughter companies Targos Advance AG and Targos Development AG and Targos Akesogen Molecular Pathology LLC. From 2002 to 2005, he was Head of Biomedical Research at the Klinikum Kassel GmbH, an activity leading to the foundation of TARGOS GmbH. Prior to this, Dr. Henkel was Vice President Research at MediGene AG, Martinsried, which he joined shortly after the foundation in 1995 and led the research programs through an IPO in 2000. From 1993-1995 he worked scientifically at Tularik Inc, San Francisco. Dr. Henkel received his scientific education and his diploma in Biology and Biochemistry from the Georg-August- Universität and the Max-Planck Institute for Experimental Medicine in Göttingen. After his graduation he performed scientific work at the Gene Center München, the Hadassah Medical School Jerusalem and the Salk Institute in San Diego. Dr. Henkel holds a PhD in Biochemistry from the Ludwig-Maximilians-Universität München. Dr. Henkel co-authored more than 30 publications, including one of the most cited Annual Reviews in Immunology. He is also author of 15 patents. Since 2004 Dr. Henkel is lecturer in Biochemistry at the Universität Kassel. He received business & management training and education in Munich and St. Gallen. Dr. Henkel is married and has a son.
Thomas C. Sauer is President & CEO of EXXERGY, a consulting firm providing first class comprehensive, cross-functional consulting and operational support to the renewable energy sector, the glass and specialty chemicals industries. In 2009, he established a group of subsidiaries around EXXERGY Green Power Holding GmbH for project development, realization and operation of renewable energy power plants. Furthermore, in 2010, Mr. Sauer established a subsidiary by the name of NEXXERGY Green Power Trading. Subsidiaries and offices of the EXXERGY group are located in Europe, the USA, Brazil, and China. Prior to establishing EXXERGY, Mr. Sauer was Chief Executive Officer of IBC Solar AG, where he particularly focused on introducing TQM (total quality management) while assuming responsibility for Purchasing, Logistics, Technical and EPC Departments, Product Management, Projects, Quality Assurance, International Business, and Special Corporate Development Tasks. From 2001 to 2004, he was Vice President Corporate Strategy and Development at Schott AG, which included his involvement in all M&A transactions of the Schott group worldwide. Thereafter he continued through 2006 at Schott in an operational responsibility as
Executive Vice President of the Business Unit Advanced Materials with global P&L- responsibility including 1.500 staff and sales turnover of approx. 150 M EUR. During this tenure,
Mr. Sauer was as well holding several advisory board positions at affiliates of the Schott group.
Voluntary and social responsibility related engagements of Mr. Sauer include his service as Chairman of PV Experts e. V., an association consisting of international expert companies and individuals that are active in the renewable energy space, particular in the solar sector.
Furthermore, he is a workgroup delegate of the German representation at IECRE, an International standardization body setting standards for photovoltaic power plants. Furthermore, through the SunSpec Alliance, Mr. Sauer is engaged in the Orange Button initiative of the US Department of Energy. Until 2012, he participated as well in efforts defining the energy policy position of the economic council of the CDU, the leading party in Germany, as well as at the American Council of Renewable Energies (ACORE).
In addition to energy related matters, Mr. Sauer has professional experience in aviation, chemical engineering, and specialty materials. Following his studies in Mechanical and Process Engineering at the Technical University Munich and in Chemical and Process Engineering at the Technical University in Karlsruhe he achieved his Masters’ Degree in Chemical Engineering at the University (TH) Karlsruhe in Germany.
Tim Lewko is the CEO and Managing Partner of Thinking Dimensions Global (TDG) and managing director of the global strategy practice. He works primarily with senior leaders of private equity, Fortune 1000 and multi-national businesses to impact sustainable strategic growth and profitability challenges. In his 15 years of international experience he has had the unique opportunity to assist over 35 CEO’s and Managing Directors across four continents with their strategic transformational issues. Tim is also a member of the board for Thomson Power Inc. (www.thomsonpower.com), a Canadian developmental stage “Cleantech” company specializing in bringing next generation hybrid electric and pure electric solutions to the marketplace for the transit industry and beyond.
Toon Bouten previously served as Vice President of Philips Electronics NV, where he led the European Consumer Division with multibillion Euro revenues in 48 EMEA countries. As Vice President of Compaq Computers he started the Compaq Consumer Division in EMEA and reached the number one market position in Europe with more than a billion Euro of revenues within six years. In early 2000, he took over the CEO position from the founder of Jobline AB, one of the first online recruiting companies and within one year successfully scaled the company to three divisions in nine countries, quadrupled revenues and listed the company on the Stockholm Stock exchange. More recently Toon served as President and CEO of GN Store Nord and GN Netcom, the Danish headset maker where he successfully redesigned its value chain and transitioned it to a scalable and well-positioned leader in the headset industry. Toon Bouten holds an engineering degree from the Technical University of Eindhoven..
Vera Calasan, CEO of Excellence AG - German Engineering, is an expert for the Industrial Internet of Things and has an MBA from a U.S. top-tier university. Vera has more than 20 years management experience in recruitment, training and technical industries. She is an innovative senior executive with strong strategic, analytical and result-driven abilities. Vera is the former CEO of an American company in Germany with responsibility for 650 mn. € in revenue and 20.000 employees. Vera has board experience in various joint venture organizations with DAX companies and is a member of the Global Advisory Board for her Alma Mater 'The University of Chicago Booth School of Business'.
Wolfgang Söhngen is founder and CEO of PAION AG and Managing Director of
PAION Deutschland GmbH. He has raised more than EUR 180 million through fund
raising and EUR 88 million through partnering.
Wolfgang has many years of experience in the pharmaceutical industry. He worked in
clinical development, project management, corporate development, and strategic
planning at Grünenthal GmbH for ten years. Before founding PAION in 2000 with his
wife Mariola, he was head of his own consulting firm, Virtueality, which specialized in
healthcare and clinical development.
In 1985, Wolfgang received his doctoral degree in medicine from RWTH Aachen
(Technical University of Aachen). He spent two years as a resident in internal
medicine and was then offered a post-doc position in cardiovascular pharmacology at
the University of Michigan, Ann Arbor (USA). He also holds a Master of Business
Communication and a Diploma in Pharmaceutical Medicine (DGPharMed).
A passionate leader, Wolf Lichtenstein joined Webtrekk as the new CEO in June 2017.
Before joining Webtrekk, Wolf Lichtenstein acted as Managing Director and CEO DACH at SAS Germany between 2008 and 2016. There he focused on the challenges presented by digitization and customer intelligence. Additionally, Wolf Lichtenstein was responsible for SAS’s activities in Israel. He joined McKinsey as a partner in September 2016, specializing in analytics.
A renowned pioneer in the field of Industry 4.0 and digital intelligence, Wolf regularly takes part in discussions at the World Economic Forum and is a member of associations like Atlantik-Brücke e.V. and United Europe. He also acts as a member of the Academic Advisory Council of Heidelberg University.
Furthermore, Wolf is an active member on the board of directors of the American Chamber of Commerce in Germany and is on the board of the German-Israeli Chamber of Industry and Commerce. He was also a board member for Apollis AG, an incubator for European wireless companies.
Originally from Heilbronn, Wolf holds degrees in psychology and computer science.
Mr. Michlin brings two decades of experience in growing biomedical organizations. His proficiency in corporate finance, capital markets and business management and development has played a crucial role in the success of leading organizations throughout the Israeli biotech industry. He joined Brainsway in 2015 serving as a director on its board providing exceptional guidance. He brings extensive expertise in steering biomedical companies to success. Yaacov possesses the right blend of strategic acumen, interpersonal skills, relationship assets and management capabilities. For the past eight years, Mr. Michlin has served as president and CEO of Yissum, the technology transfer company of Israel's Hebrew University in Jerusalem. At Yissum, he facilitated and oversaw numerous corporate transactions and initiatives in partnership with corporations across the globe and funded and served as chairman of few companies including Integra Holdings, a healthcare investment company and Agrinnovation an investment fund focusing on Agriculture and food sciences. Mr. Michlin also served as chairman for QLIGHT Nanotech Ltd., a developer of semiconductors and nanocrystals, which he led from the company's founding until its acquisition by Merck. He also served as co-chairman of ITTN, the Israeli organization for technology transfer. Prior to Yissum, Mr. Michlin practiced as a corporate lawyer, advising on major corporate matters including mergers and acquisitions, capital raising and initial public offerings for clients including mainly Teva Pharmaceutical Industries. Mr. Michlin is a lawyer and economist by training, and holds an MBA from the Technion in high-tech company management.
With GCH Hotel Group since 2011
Education and training: Yaron holds a BA from the Hebrew University in Jerusalem and a diploma in Hotel Management from the Technion - Israel Institute of Technology. He is currently a member of the European Hotel Managers Association (EHMA).
Yaron Ashkenazi has extensive international experience in the hospitality industry. He currently holds the position of Chief Executive Officer at GCH Hotel Group, one of the fastest growing hotel management companies in Germany. Yaron began his tenure with GCH Hotel group in 2011, where he has held the titles of Area Vice President and Chief Operating Officer prior to being appointed CEO. Before joining GCH Hotel Group, Yaron held the position of General Manager in one of the leading hotel complexes in Europe. There he was responsible for taking over, planning, positioning, and managing a hotel complex which included a 5-star hotel, an apartment hotel, a casino, a fitness centre, and a commercial promenade.
Yaron has also held several managerial positions in the hotel business in Israel and Europe - as a training manager, an HR Manager, a Food & Beverage Manager and General Manager. He sees enormous potential for the GCH Hotel Group. "The strategy for further growth is to develop strong connections between partners, employees and investors."
Yaron Werber, M.D., MBA, has served as our chief business officer since July 2016, as
our chief financial officer since June 2015, as our secretary since July 2015 and as our
treasurer since April 2017. Prior to joining us, Dr. Werber worked at Citigroup Global
Markets Inc. from March 2004 to June 2015, where he most recently served as a
managing director, starting December 2011, and the head of U.S. healthcare and biotech
equity research teams. Previously, Dr. Werber was a senior biotech analyst and vice
president at SG Cowen Securities Corporation. He began his career in academic
research and was director of business development at NotifyMD, Inc., an e-health
company. Dr. Werber earned his B.S. in Biology from Tufts University and a combined
M.D./MBA degree from Tufts University School of Medicine.
Mr. Cristian Longo is the CEO at Link Hospitality Corp, He is a successful leader in the hospitality industry with over 18 years of experience. Proactive hands-on management style with extensive team leadership and personal development skills. Motivator with ability to move a group toward a consensus.
Able to direct a work force while providing support staff to accomplish company goals and meet deadlines. Excellent administrative skills to include, Budget preparation, effective scheduling, as well as inventory controls. Extensive experience in team building and negotiation.
Daniel Leon is a business and social entrepreneur with a proven track record of growing early-stage companies and building organizations from the ground up. He has founded and led multiple companies and not-for- profit organizations. Currently, Daniel is a founder and President of Celsius Networks and a partner with Governing Dynamics, VC firm that invests in - and scale - Israeli high-tech companies. Prior to Governing Dynamics, he was founder and CEO of Atlis Labs, a venture-backed local discovery platform and before that he served as CEO of robotics company Beyon3D. Previously, Daniel served as GM Mobile, of Ground Link, which raised more than $30 million in funding during his tenure. He started his career as vice president of the Gallup Organization.
Daniel holds a degree in Economics from Brown University. He has one daughter and splits his time between
New York and Tel Aviv.
David is CEO of Optimatum - a vendor management firm for the HR supply chain, providing end to end solutions in employee sponsored healthcare, retirement plans, HR systems and M&A/Transitional services.
Through our turnkey solution we deliver results for organizations across financial and operational functions with our multi-disciplinary approach including forensic data analysis, process realignment and ongoing monitoring. Optimatum drives performance and operational efficiencies through vendor accountability. Since our inception we continue to serve mid to large sized organizations across all industries and sectors.
David brings 27 years of experience and is an industry thought leader who founded Optimatum Solutions in 2007 after recognizing a need for strategic vendor management within the HR supply chain. He maintains strong relationships within the industry and is recognized for his innovative thinking and strategic approach to client matters.
He has previously served in senior roles within organizations such as Capital H Group and other advisory firms.
Edward has over 15 years of entrepreneurial experience in the technology and services industry. In 1996, Edward co-founded Net@Work, offering a service oriented approach to IT and network support. As an owner of an emerging business, Edward completely understands the value of executive level involvement-and its contribution to a project’s ultimate success-from the earliest planning stages through completion and beyond. Before starting Net@Work Edward worked in commercial and investment banking for Republic National Bank and Natwest Markets where he managed accounting for real-estate properties and restructured Chart of Accounts respectively. Edward received his MBA in Finance from Baruch College, NY.
Ed is responsible for overall agency leadership and has been instrumental in both driving Peppercomm’s business success over the last 20 years and securing its position as the No. 1 Workplace in New York, 2012 by Crain’s New York Business. He continues to lead the agency in its evolution from a strategic public relations firm to an integrated communications and marketing agency. Ed has led the firm’s acquisition strategy over the last five years and continues to provide overall direction to operations, finances, new services development, client service, new business and broader strategy.
Ed was named on B2B Magazine’s Who’s Who list and was a finalist for Ernst & Young’s prestigious Entrepreneur of the Year award. Ed provides expert commentary for such media as: CNN, FOX News, Marketing News, BrandWeek, Fast Company, Entrepreneur, Inc., PRNews and PRWeek. His passion for continual innovation led to Peppercomm’s creation and growth of its measurement and research offerings. He serves as a trustee for Drew University, is a board member of the Council of PR Firms Counselors Academy, and sits on the planning committee of the Council of PR Firms. His nonprofit work includes board positions with Little Kids Rock and My Good Deed.org.
Eugene Babenko is an established pharmaceutical executive with more than 20 years of experience in the pharmaceutical arena. Eugene brings an extensive wealth of knowledge in specialty pharmaceuticals and in various niche therapeutic areas.
Eugene spent 12 years working in a variety of capacities at various major pharmaceutical companies, including GlaxoSmithKline, Novartis and Gilead Sciences, Inc. Ten years ago, he along with 2 partners, founded Quality Specialty Pharmacy (QSP), a successful retail specialty pharmacy chain focusing on disease states such as dermatology, HIV, and hepatitis B and C. QSP's focus is customer-driven and provides affordable, high-quality care for complex chronic conditions. The company prides itself on its commitment to compassion, integrity and quality - measuring its success through healthy outcomes, satisfied clients and clarity of vision to support the hundreds of new life-changing biopharmaceutical drugs that will help patients in the decades to come. QSP is currently licensed and operating in 45 states.
Jason M. Hill is an accomplished entrepreneur with 17 years of success in the information technology, consulting, staffing, and recruitment process outsourcing industries. As a project manager/consultant and recruitment specialist, Mr. Hill has managed and placed contract and full-time professionals in positions ranging from entry-level to executive management.
Mr. Hill's clients include firms within the following industries: Information Technology, Medical/Healthcare, Consulting, Green Initiatives/Renewable Energies, Banking/Financial Services, Transportation, Bio-Technology, Pharmaceutical, Legal, and Retail.
John Cavitt is Founder and CEO of Covenant Testing Technologies in Houston, TX. John has a long history of entrepreneurship and leadership. Out of a love for people, John began as a Chemistry teacher in Midland Texas where he sharpened his skill to motivate and lead. His first business was in high school with a shaved ice stand and lawn business and has launched multiple businesses since then including a chain of hair salons in West Texas. An import/export business in Mexico. While in Midland, John joined Oil States International, a leading oil and gas services and technology business. There he gained executive management experience and moved to Select Energy Services, a leading water solutions and technology company for oil and gas development. He served as the Vice President of the Well Testing and Well Flow Management Division, growing the division to the largest in the US.
In May, 2013, John Partnered with Ken Hersh and NGP, a private equity firm out of Irving Texas. He founded Covenant Testing Technologies greenfield with his American Express card and a vision to create an innovative and employee centric oil and gas services technology and service company. Since then, through a significant commodities downturn and distressed market, John and Covenant have capitalized on an innovative culture and multiple strategic distressed asset deals to become the largest well flow management company in the US oil and gas market. With over $100Million in revenue and 700 employees, Covenant is postitioned uniquely in the most important areas of the energy market and provide innovative and environmentally responsible techniques with superior service to its clients.
John is married to Leah with 5 kids (4 boys and a girl all 9 and under), 3 of whom have a rare eye retinal disorder rendering them legally blind. In his spare time, he fights for this cause with his work toward a gene therapy with the Blue Cone Monocromacy Family Foundation. He and his family also work to provide technical job skill training to the deeply impoverished through organizations in Matagalpa, Nicaragua.
Dr. Jonathan Javitt serves as Founder and CEO of NeuroRx, a clinical stage pharma company that is in phase 2b/3 clinical trials with NRX-101, an FDA Fast Track, first-in-class drug targeting suicidality in bipolar depression. He has a 30-year history of combining clinical understanding with expertise in medical device and drug development, health information technology, health policy, and health economics. He has played senior roles on pharmaceutical and medical device development teams for Merck, Allergan, Eyetech, Mannkind, Novartis, Pharmacia, and Pfizer.
Dr. Javitt has been a founder of 6 health informatics and analytics companies that have gone on to public exits. In each of those endeavors, he has focused on the use of leading edge technology to improve clinical care processes. He has served the administration of George W. Bush in positions related to health policy and national security. Under President Clinton, he was appointed to the White House Health Reform Task Force.
Jonathan pioneered the use of outcomes and health economic research in ophthalmologic drug and device development. He wrote the blueprint for the FDA’s Sentinel Systems program and served for 10 years as an expert consultant to the Medicare program. His experience includes regulatory expertise in FDA and CE compliance with the drug and device approval process and quality system management.
After receiving his A.B. with honors in Biochemistry from Princeton University, he completed medical training at Cornell, Harvard, the Wills Eye Hospital, and the Wilmer Ophthalmological Institute of Johns Hopkins Universitiy. He has served as Professor of Ophthalmology and Public Policy on the full-time faculties of Georgetown and Johns Hopkins Universities and remains an adjunct Professor at Johns Hopkins. In his academic career he directed and participated in more than $20 million of federally-funded research focused on outcomes of, and delivery of, health care including diseases of the eye, diabetes, and breast cancer. He authored the first book on computers in medicine in 1984 and has published more than 200 scientific works in the New England Journal of Medicine, the Journal of the American Medical Association, and numerous other peer-reviewed publications in addition to a novel. He is lead inventor on seven US patents.
In 2015 he was named Alumnus of Merit of the Harvard School of Public Health, Harvard’s top award for public health service.
Lawrence Obstfeld is CEO of Image Navigation which has developed the FDA-approved IGI system for CT-navigated oral-maxillofacial surgery and the DentSim - augmented reality dental simulator. Also a founder of BetaGene, Inc. and Gladius Pharmaceuticals.
Mikhail joined Atlant Clinical in 2012 as Chief Executive Officer and as a member of the Board of Directors. Prior to Atlant Clinical he worked at GlaxoSmithKline where he started as a clinical research assistant, later becoming a local study manager in the oncology group. He subsequently joined the Moscow Sales Department, where he rose to become Regional Market Access Director. Mikhail graduated from Lomonosov Moscow State University with Master degrees in biochemistry and management.
Nathan is the Founder and President of Sunrise Financial Group Inc., a growth engine for Israeli startups.
Besides founding Sunrise Financial Group, Nathan has personally invested in over 126 startups over 24 years, 76 of which in Israel, 40 of which in California, 3 of which in cyber so far, and 5 of them in the Cloud. Nathan also cofounded with IBM in 2014 the IBM AlphaZone High Tech Accelerator at IBM HQ in Petach Tikva, IBM's first ever accelerator in the world. Notable personal investments include Concentric Research, Arena Pharmaceuticals, On-Track Innovations and Enzymotec. Nathan’s investment strategy involves strong advisory presence and active support, encouraging strategic partnerships for his portfolio companies.
From 1992, through the end of 2016, Sunrise Securities raised in excess of $6 billion for over 60 domestic and international public and private companies, using a variety of financing instruments.
Nathan was graduated Cum Laude from Harvard College in 1982, and speaks English, French, Spanish and Hebrew. He also serves on a variety of charitable boards for projects involving the cancer care, education and the developmentally disabled.
Dr. Peter Kash Ed.D/MBA has been in the field of biotechnology for over almost 30 years helping fund more than a dozen biopharmaceutical companies several with FDA approvals. Besides a BS in Management Science and an MBA in Finance he also holds a Doctorate in Education from the Azrieli School of Yeshiva University. He has served as an adjunct Professor of Entrepreneurship at the Wharton School of Business, and has been a Visiting Professor at Nihon University in Tokyo Japan and in 2015 as a Visiting Professor at Hebrew University in Jerusalem. He is authored several books distributed in 8 languages in more than 30 countries, his most recent release is Take Two Tablets Medicine from the Bible now in Hebrew, English and Chinese.
Solomon has 20 Years of leadership experience in Software Product Development and Product Market Launch. For the last 14 years Leading and managing the International IT Services Group- "AllStars-IT Group" (www.allstars-it.com) and its subsidiaries : TestPro, Cyber-Stars and AllStars-IT Ukraine (a leading international IT offshore services company Located in Kiev-Ukraine with back offices in USA, Europe and Israel, Specialities: In-depth understanding of emerging technologies in the Software Development & Software Testing)
Along his career Solomon has build a solid network of hundreds of international clients ensuring successful delivery of multidisciplinary technological projects in various verticals: HighTech, Defense, Finance, Governmet and Telecom sectors, mainly in the US, UK, Germany and Israel, while conducting a high-scalable ALM.
Under Solomon's supervision : The group's Financial and HR management of hundreds of Engineers, providing his business on-going transformation for boosting profits and ensuring a sustainable growth while managing global affiliate programs and business relations with international partners.
Connecting the Pharma & Healthcare industry with compliant innovation has been Febbo’s trademark in over 18 years of leading health service & technology companies. In 1999, he co-founded MedPanel, a market intelligence and communication provider to the biomedical & medical device industries. When Febbo sold it in 2007 to Merriman Capital, he held dual roles as COO of the bank and CEO of Digital Capital Network which he launched pioneering digital compliance & transparency in the financial industry.
Febbo is also founder of Plexuus, an early stage payment processing platform for medical professionals with Sunshine Act-related activities. Currently, he holds the position of CEO at OptimizeRX and continues to discover, innovate and connect both products and people to meaningful experiences to improve health outcomes. Febbo has most recently joined MIT linQ as a faculty member. LinQ is a new collaborative initiative focused on increasing the potential of innovative research to benefit society and the economy. linQ’s portfolio of international innovation programs demonstrates a new paradigm for technology research and training. Thus far, Febbo has participated in two of these programs, IMPACT and Idea2 global.
Febbo holds a Bachelor of Arts in International Studies from Dickinson College, in Pennsylvania and serves on the board of The United Nations of Greater Boston, a non-profit focused on building global citizens within inner-city schools in Massachusetts.
On Monday, November 13th, YJP will host its renowned CEO Forum in Europe for the first time. Join us in Berlin for two days of dynamic conversations, learning and networking with top-level business executives from both sides of the Atlantic Ocean. We will be focusing on the themes of Leadership, Innovation, and Diversity. There will also be a special focus on the Healthcare industry. YJP's CEO Forums, our signature events, are reserved for high-level business leaders and entrepreneurs to help each other become better leaders so that they can return to the companies they lead better equipped to ensure success.
Our CEO events are known for opening doors for participants to forge long-lasting, sincere relationships with top talent and c-level executives. The confidential and intimate format allows you to interact on a deeper and more meaningful level with like-minded executives to explore important topics related to leadership and innovation. Don't miss out on this unique opportunity to experience why our CEO Forums are known in New York City as the premier community for CEOs!
Bayer - Berlin
This event starts on Monday November 13th at 4:00 PM.